var title_f34_25_35216="Tennis elbow injection";
var content_f34_25_35216=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F75451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F75451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 496px\">",
"   <div class=\"ttl\">",
"    \"Tennis elbow\" injection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 476px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With the elbow flexed and pronated, the needle is inserted at the most tender area on the anterolateral aspect of the external condyle of the humerus. A combination of corticosteroid and local anesthetic is injected in several areas.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from Owen, DS. Aspiration and injection of joints in soft tissue. In: Textbook of Rheumatology, 4th edition, Kelley, WN, Harris, ED Jr, Ruddy, S, et al (Eds), WB Saunders, Philadelphia 1993. p.545.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_25_35216=[""].join("\n");
var outline_f34_25_35216=null;
var title_f34_25_35217="Peripheral IV placement 2";
var content_f34_25_35217=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F62529&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F62529&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Peripheral IV placement: Preparation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Place a tourniquet proximal to the venipuncture site and clean the involved area thoroughly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Frank, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_25_35217=[""].join("\n");
var outline_f34_25_35217=null;
var title_f34_25_35218="Weak OK sign";
var content_f34_25_35218=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F83562&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F83562&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Weak OK sign",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 405px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anterior interosseus nerve injury causes flattening of the OK sign due to the loss of thumb and index finger flexion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Bassett, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_25_35218=[""].join("\n");
var outline_f34_25_35218=null;
var title_f34_25_35219="MCL grade3 injury MRI";
var content_f34_25_35219=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F61894&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F61894&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 595px\">",
"   <div class=\"ttl\">",
"    MRI of Grade 3 medial collateral ligament injury",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 575px; height: 284px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These MRI images show a complete transverse tear through the MCL. The arrow points to the area of focal interruption of the normal dark fibers, with hemorrhage and edema surrounding the MCL. Fibers at the tear site are wavy. Note that it may be difficult to distinguish high-grade Grade 2 and Grade 3 tears.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mary Hochman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_25_35219=[""].join("\n");
var outline_f34_25_35219=null;
var title_f34_25_35220="Ciclesonide (nasal): Drug information";
var content_f34_25_35220=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ciclesonide (nasal): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/37/27221?source=see_link\">",
"    see \"Ciclesonide (nasal): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?3/33/3604?source=see_link\">",
"    see \"Ciclesonide (nasal): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8002704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Omnaris&reg;;",
"     </li>",
"     <li>",
"      Zetonna&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8002705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Omnaris&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8007837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Nasal",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8002756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     <b>",
"      Perennial allergic rhinitis, seasonal allergic rhinitis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omnaris&reg;: 2 sprays (50 mcg/spray) per nostril once daily; maximum: 200 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zetonna&trade;: 1 spray (37 mcg/spray) per nostril once daily; maximum: 74 mcg/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8002755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?3/33/3604?source=see_link\">",
"      see \"Ciclesonide (nasal): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Perennial allergic rhinitis:",
"     </b>",
"     Children &ge;12 years: Refer to adult dosing:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Seasonal allergic rhinitis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     Children &ge;6 year: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8002757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15682646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8002800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, intranasal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zetonna&trade;: 37 mcg/inhalation (6.1 g) [contains ethanol; 60 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, intranasal [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Omnaris&reg;: 50 mcg/inhalation (12.5 g) [120 metered actuations]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8002706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8002782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Intranasal: Blow nose to clear nostrils. Insert applicator into nostril, keeping bottle upright, and close off the other nostril. Breathe in through nose. While inhaling, press pump to release spray. Avoid spraying directly onto the nasal septum or into eyes. Discard after the \"discard by\" date or after labeled number of doses has been used, even if bottle is not completely empty.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omnaris&reg;: Shake bottle gently before using. Prime pump prior to first use (press 8 times until fine mist appears) or if spray has not been used in 4 consecutive days (press 1 time or until a fine mist appears). Nasal applicator may be removed and rinsed with warm water to clean.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zetonna&trade;: Use nasal canister with supplied nasal actuator only. Prime pump prior to first use (press 3 times until fine mist appears) or if spray has not been used in 10 consecutive days (press 3 times or until a fine mist appears). If canister and actuator become separated, spray 1 test spray in air before using. Clean outside of nose piece with a clean, dry tissue or cloth weekly; do not wash or put in water.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8002708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Management of seasonal and perennial allergic rhinitis",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F14225162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct to antibiotics in empiric treatment of acute bacterial rhinosinusitis (ABRS) (Chow, 2012)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8002722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (&le;11%), fever (children 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Epistaxis (&le;11%), nasopharyngitis (&le;11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dysphonia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (&ge;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urinary tract infection (&ge;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Back pain (&ge;2%), muscle strain (&ge;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Upper respiratory infection (&le;9%), nasal congestion (&le;6%),  sinusitis (&le;6%), nasal discomfort (3% to 6%), pharyngolaryngeal pain (&le;5%), hoarseness (&ge;3%), pneumonia (&ge;3%), bronchitis (&ge;2%), cough (&ge;2%), nasal septum disorder (&ge;2%), pharyngitis (&ge;2%), paradoxical bronchospasm (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Influenza (&ge;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): ALT increased, angioedema (with swelling of lip/pharynx/tongue), bruising, candidiasis (nasal/pharyngeal), cataract, chest discomfort, dizziness, dry throat, dysgeusia, dyspepsia, GGT increased, growth suppression, intraocular pressure increased, nasal ulcer, palpitation, rash, rhinorrhea, throat irritation, WBC increased, weight gain, wound healing impaired, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8002709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ciclesonide or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8002710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Adrenal suppression: When used at excessive doses, may cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Delayed wound healing: Avoid nasal corticosteroid use in patients with recent nasal septal ulcers, nasal surgery or nasal trauma until healing has occurred.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	 Immunosuppression: Prolonged use of corticosteroids may increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Exposure to chickenpox should be avoided; corticosteroids should be used with caution, if at all, in patients with ocular herpes simplex, latent tuberculosis, and/or TB reactivity, or in patients with untreated fungal, viral, or bacterial infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	 Local nasal effects: Nasal septal perforation, nasal ulceration, epistaxis, and localized",
"     <i>",
"      Candida albicans",
"     </i>",
"     infections of the nose and/or pharynx may occur. Monitor patients periodically for adverse nasal effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	 Ocular disease: Increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with intranasal corticosteroid use; use with caution in patients with a history of increased intraocular pressure, cataracts and/or glaucoma. Consider routine eye exams in chronic users or in patients who report visual changes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	Pediatrics: Intranasal corticosteroids may cause a reduction in growth velocity in pediatric patients (~1 cm per year [range: 0.3-1.8 cm per year] and related to dose and duration of exposure). To minimize the systemic effects of intranasal corticosteroids, each patient should be titrated to the lowest effective dose. Growth should be routinely monitored in pediatric patients.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8002734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8002735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8043197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8043198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were reported following subcutaneous administration of ciclesonide in animal reproduction studies. The extent of intranasal absorption of ciclesonide systemically is low but variable. Hypoadrenalism may occur in infants born to mothers receiving corticosteroids during pregnancy. Intranasal corticosteroids may be used in the treatment of rhinitis during pregnancy (Wallace, 2008).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8043200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13766079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Systemic corticosteroids are excreted in human milk. It is not known if sufficient quantities of ciclesonide are absorbed following nasal inhalation to produce detectable amounts in breast milk; however, oral absorption is limited (&lt;1%). The use of inhaled corticosteroids is not considered a contraindication to breast-feeding (NAEPP, 2005).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8002803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aerosol solution",
"     </b>",
"     (Zetonna Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     37 mcg/ACT (6.1 g): $136.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Omnaris Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mcg/ACT (12.5 g): $136.85",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F11390226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Omnaris (AR, AU, BR, HK, MY, PH, SG)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8002743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: 24-48 hours; further improvement observed over 1-2 weeks in seasonal allergic rhinitis or 5 weeks in perennial allergic rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Minimal systemic absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Ciclesonide hydrolyzed to active metabolite, des-ciclesonide via esterases in nasal mucosa and lungs; further metabolism via hepatic CYP3A4 and 2D6",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: &lt;1%",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chow AW, Benninger MS, Brook I, et al, &ldquo;IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012, 54(8):e72-112.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/25/35220/abstract-text/22438350/pubmed\" id=\"22438350\" target=\"_blank\">",
"        22438350",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      NAEPP Working Group Report on &ldquo;Managing Asthma During Pregnancy: Recommendations for Pharmacologic Treatment,&rdquo; National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 05-5236, March 2005. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nave R, Wingertzahn MA, Brookman S, et al, &ldquo;Safety, Tolerability, and Exposure of Ciclesonide Nasal Spray in Healthy and Asymptomatic Subjects with Seasonal Allergic Rhinitis,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2006, 46 (4):461-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/25/35220/abstract-text/16554455/pubmed\" id=\"16554455\" target=\"_blank\">",
"        16554455",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wallace DV, Dykewicz MS, Bernstein DI, et al, &ldquo;The Diagnosis and Management of Rhinitis: An Updated Practice Parameter,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 2008, 122(2 Suppl):1-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/25/35220/abstract-text/18662584/pubmed\" id=\"18662584\" target=\"_blank\">",
"        18662584",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9043 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-213.131.41.98-64F77B4D5B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_25_35220=[""].join("\n");
var outline_f34_25_35220=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002704\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002705\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8007837\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002756\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002755\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002757\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682646\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682647\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002800\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002706\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002782\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002708\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14225162\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002722\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002709\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002710\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002734\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002735\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8043197\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8043198\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8043200\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13766079\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002803\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390226\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002743\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9043\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9043|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/37/27221?source=related_link\">",
"      Ciclesonide (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?3/33/3604?source=related_link\">",
"      Ciclesonide (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?34/5/34902?source=related_link\">",
"      Ciclesonide (oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?34/34/35365?source=related_link\">",
"      Ciclesonide (oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/26/22949?source=related_link\">",
"      Ciclesonide (oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_25_35221="Zonisamide: Patient drug information";
var content_f34_25_35221=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Zonisamide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/2/10279?source=see_link\">",
"     see \"Zonisamide: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/52/25415?source=see_link\">",
"     see \"Zonisamide: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F236246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zonegran&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10018106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691482",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or control seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691952",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat manic low mood (depression).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703152",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to zonisamide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696966",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow laws about driving with a seizure problem.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697053",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are on a ketogenic diet, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have soft, brittle bones (osteoporosis), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort with this drug. This drug may not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698326",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not sweating during activities or in warm temperatures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698605",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Back pain, belly pain, or blood in the urine. May be signs of a kidney stone.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698512",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If seizures are worse or not the same after starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695700",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow capsule whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696460",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. This could cause seizures. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11160 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-6250843016-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_25_35221=[""].join("\n");
var outline_f34_25_35221=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236246\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018106\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018108\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018107\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018112\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018113\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018115\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018110\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018111\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018116\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018117\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?10/2/10279?source=related_link\">",
"      Zonisamide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/52/25415?source=related_link\">",
"      Zonisamide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_25_35222="Trunks and cords of the brachial plexus";
var content_f34_25_35222=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F50576&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F50576&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    Trunks and cords of the brachial plexus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 497px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_25_35222=[""].join("\n");
var outline_f34_25_35222=null;
var title_f34_25_35223="Cardiorenal syndrome: Definition, prevalence, diagnosis, and pathophysiology";
var content_f34_25_35223=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cardiorenal syndrome: Definition, prevalence, diagnosis, and pathophysiology",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/25/35223/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/25/35223/contributors\">",
"     Michael S Kiernan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/25/35223/contributors\">",
"     James E Udelson, MD, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/25/35223/contributors\">",
"     Mark Sarnak, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/25/35223/contributors\">",
"     Marvin Konstam, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/25/35223/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/25/35223/contributors\">",
"     Stephen S Gottlieb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/25/35223/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/25/35223/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/25/35223/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2022629\">",
"    <span class=\"h1\">",
"     DEFINITION AND CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of important interactions between heart disease and kidney disease. The interaction is bidirectional as acute or chronic dysfunction of the heart or kidneys can induce acute or chronic dysfunction in the other organ. The clinical importance of such relationships is illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mortality is increased in patients with heart failure (HF) who have a reduced glomerular filtration rate (GFR). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/26/44456?source=see_link&amp;anchor=H28486377#H28486377\">",
"       \"Cardiorenal syndrome: Prognosis and treatment\", section on 'Reduced GFR and prognosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with chronic kidney disease have an increased risk of both atherosclerotic cardiovascular disease and heart failure, and cardiovascular disease is responsible for up to 50 percent of deaths in patients with renal failure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35223/abstract/1,2\">",
"       1,2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=see_link&amp;anchor=H1#H1\">",
"       \"Chronic kidney disease and coronary heart disease\", section on 'Introduction'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute or chronic systemic disorders can cause both cardiac and renal dysfunction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The term cardiorenal syndrome (CRS) has been applied to these interactions, but the definition and classification have not been clear. A 2004 report from the National Heart, Lung, and Blood Institute defined CRS as a condition in which therapy to relieve congestive symptoms of HF is limited by a decline in renal function as manifested by a reduction in GFR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35223/abstract/3\">",
"     3",
"    </a>",
"    ]. The reduction in GFR was initially thought to result from a reduction in renal blood flow. However, various studies have demonstrated that cardiorenal interactions occur in both directions and in a variety of clinical settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35223/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H49850194\">",
"     'Pathophysiology'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The different interactions that can occur led to the following classification of CRS that was proposed by Ronco and colleagues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35223/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type 1 (acute) &mdash; Acute HF results in acute kidney injury (AKI, previously called acute renal failure).",
"     </li>",
"     <li>",
"      Type 2 &mdash; Chronic cardiac dysfunction (eg, chronic HF) causes progressive chronic kidney disease (CKD, previously called chronic renal failure).",
"     </li>",
"     <li>",
"      Type 3 &mdash; Abrupt and primary worsening of kidney function due, for example, to renal ischemia or glomerulonephritis causes acute cardiac dysfunction, which may be manifested by HF.",
"     </li>",
"     <li>",
"      Type 4 &mdash; Primary CKD contributes to cardiac dysfunction, which may be manifested by coronary disease, HF, or arrhythmia.",
"     </li>",
"     <li>",
"      Type 5 (secondary) &mdash; Acute or chronic systemic disorders (eg, sepsis or diabetes mellitus) that cause both cardiac and renal dysfunction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prevalence of impaired renal function in patients with HF, the diagnosis of CRS, and the mechanisms by which acute HF leads to worsening kidney function (type 1 CRS) will be reviewed here. However, it may be difficult to distinguish between type 1 and type 2 CRS (chronic HF), and similar mechanisms may apply to type 2. Issues related to the prognosis and treatment of type 1 or 2 CRS are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/26/44456?source=see_link\">",
"     \"Cardiorenal syndrome: Prognosis and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61342639\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart failure (HF) is frequently accompanied by a reduction in glomerular filtration rate (GFR) via mechanisms that will be described below. (See",
"    <a class=\"local\" href=\"#H49850194\">",
"     'Pathophysiology'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The prevalence of moderate to severe kidney impairment (defined as a GFR less than 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    ; normal more than 90",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    ) is approximately 30 to 60 percent in patients with HF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35223/abstract/6-10\">",
"     6-10",
"    </a>",
"    ]. The following observations are illustrative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a systematic review of 16 studies of more than 80,000 hospitalized and nonhospitalized patients with HF, moderate to severe kidney impairment (defined as an estimated GFR less than 53",
"      <span class=\"nowrap\">",
"       mL/minute,",
"      </span>",
"      a serum creatinine of 1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [132",
"      <span class=\"nowrap\">",
"       micromol/L]",
"      </span>",
"      or higher, or a serum cystatin C of 1.56",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      or higher) was present in 29 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35223/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Acute Decompensated Heart Failure National Registry (ADHERE) database reported data on over 100,000 patients with HF requiring hospitalization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35223/abstract/9\">",
"       9",
"      </a>",
"      ]. Approximately 30 percent had a diagnosis of chronic kidney disease (defined as a serum creatinine greater than 2.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [177",
"      <span class=\"nowrap\">",
"       micromol/L]).",
"      </span>",
"      The mean estimated GFR was 55",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per m",
"      <sup>",
"       2",
"      </sup>",
"      , and only 9 percent had a normal estimated GFR (defined as greater than 90",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73m",
"      <sup>",
"       2",
"      </sup>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35223/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to these baseline observations, patients undergoing treatment for acute or chronic HF frequently develop an increase in serum creatinine, which fulfills criteria for type 1 or type 2 CRS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35223/abstract/11-20\">",
"     11-20",
"    </a>",
"    ]. In different series, approximately 20 to 30 percent of patients developed an increase in serum creatinine of more than 0.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (27",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35223/abstract/11,12,14,16,18\">",
"     11,12,14,16,18",
"    </a>",
"    ], and, in one report, 24 percent had an increase of 0.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (44",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    or more [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35223/abstract/14\">",
"     14",
"    </a>",
"    ]. Risk factors for worsening kidney function during admission for HF include a prior history of HF or diabetes, an admission serum creatinine of 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (133",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    or higher, and uncontrolled hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35223/abstract/12,13,21\">",
"     12,13,21",
"    </a>",
"    ]. The rise in serum creatinine usually occurs in the first three to five days of hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35223/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2022657\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impaired kidney function in patients with heart failure (HF) is defined as a reduction in glomerular filtration rate (GFR). The most common test used to estimate GFR is the serum creatinine concentration. However, older and sicker patients often have a reduction in muscle mass and therefore in creatinine production. Thus, the GFR may be substantially reduced in patients who have a serum creatinine that is in the normal range or only mildly elevated. Estimation equations are available that provide a better estimate of GFR than the serum creatinine alone by including known variables that affect the serum creatinine independent of GFR (eg, age, weight, sex). Another alternative to serum creatinine is measurement of serum cystatin C, which is an endogenous proteinase inhibitor synthesized and released into plasma at a constant rate by all nucleated cells. All of these tests require that the serum creatinine or cystatin C concentration be",
"    <strong>",
"     stable",
"    </strong>",
"    ; they cannot be used to estimate GFR in a patient who has a rising serum creatinine. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link\">",
"     \"Assessment of kidney function\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Among patients with HF who have an elevated serum creatinine",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a reduced estimated GFR, it is important to distinguish between underlying kidney disease and impaired kidney function due to the cardiorenal syndrome (CRS). This distinction may be difficult and some patients have both underlying chronic kidney disease and CRS.",
"   </p>",
"   <p>",
"    Findings suggestive of underlying kidney disease include significant proteinuria (usually more than 1000",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    an active urine sediment with hematuria with or without pyuria or cellular casts,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    small kidneys on radiologic evaluation. However, a normal urinalysis, which is typically present in CRS without underlying kidney disease, can also be seen in variety of renal diseases including nephrosclerosis and obstructive nephropathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35785?source=see_link&amp;anchor=H14#H14\">",
"     \"Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease\", section on 'Urinary findings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Measurement of the urine sodium concentration also may be helpful. A urine sodium concentration below 25",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    would be expected with HF, since renal perfusion is reduced with associated activation of the renin-angiotensin-aldosterone and sympathetic nervous systems, both of which promote sodium retention. However, higher values may be seen with concurrent diuretic therapy if the measurement is made while the diuretic is still acting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35785?source=see_link&amp;anchor=H16#H16\">",
"     \"Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease\", section on 'Urine sodium excretion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49850194\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of factors can contribute to a reduction in glomerular filtration rate (GFR) in patients with heart failure (HF) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35223/abstract/4,16,22,23\">",
"     4,16,22,23",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_figure graphicRef66634 \" href=\"mobipreview.htm?10/51/11063\">",
"     figure 1",
"    </a>",
"    ). The major mechanisms that have been evaluated include neurohumoral adaptations, reduced renal perfusion, increased renal venous pressure, and right ventricular dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2022664\">",
"    <span class=\"h2\">",
"     Neurohumoral adaptations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impaired left ventricular function leads to a number of hemodynamic derangements, including reduced stroke volume and cardiac output, arterial underfilling, elevated atrial pressures and venous congestion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35223/abstract/24\">",
"     24",
"    </a>",
"    ]. These hemodynamic derangements trigger a variety of compensatory neurohormonal adaptations including activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system and increases in the release of vasopressin (antidiuretic hormone), and endothelin-1 which promote salt and water retention and systemic vasoconstriction. These adaptations overwhelm the vasodilatory and natriuretic effects of natriuretic peptides, nitric oxide, prostaglandins, and bradykinin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35223/abstract/20,22,25\">",
"     20,22,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neurohumoral adaptations can contribute to preservation of perfusion to vital organs (the brain and heart) by maintenance of systemic pressure via arterial vasoconstriction in other circulations, including the renal circulation, and by increasing myocardial contractility and heart rate. However, systemic vasoconstriction increases cardiac afterload, which reduces cardiac output, which can further reduce renal perfusion. The maladaptive nature of these adaptations is evidenced by the slowing of disease progression and reduction in mortality with the administration of angiotensin inhibitors and beta blockers in patients with HF due to systolic dysfunction. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32455?source=see_link\">",
"     \"Pathophysiology of heart failure: Neurohumoral adaptations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16090?source=see_link\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/39/2680?source=see_link\">",
"     \"Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12905?source=see_link\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2022685\">",
"    <span class=\"h2\">",
"     Reduced renal perfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, an original definition described the cardiorenal syndrome (CRS) as a disorder in which therapy to relieve congestive symptoms of HF (eg, loop diuretics) is limited by a reduction in glomerular filtration rate (GFR); the fall in GFR was thought to result from a decline in cardiac output of as much as 20 percent due to the reduction in ventricular preload [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35223/abstract/3,26\">",
"     3,26",
"    </a>",
"    ]. A similar reduction in renal perfusion may be induced by acute decompensated HF prior to treatment. However, some patients initially have little or no reduction in cardiac output with loop diuretic therapy because they are on the flat part of the Frank-Starling curve in which changes in left ventricular end-diastolic pressure have little or no effect on cardiac performance (",
"    <a class=\"graphic graphic_figure graphicRef58693 \" href=\"mobipreview.htm?32/56/33677\">",
"     figure 2",
"    </a>",
"    ), while others have an increase in GFR following diuretic therapy that may be mediated by a reduction in renal venous pressure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    right ventricular dilatation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23076?source=see_link&amp;anchor=H6#H6\">",
"     \"Pathophysiology of heart failure: Left ventricular pressure-volume relationships\", section on 'Pressure-volume relationships in heart failure'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H2022699\">",
"     'Increased renal venous pressure'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H124107751\">",
"     'Right ventricular dilatation and dysfunction'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    However, worsening kidney function in patients with HF is not solely due to reduced renal perfusion induced by a low cardiac output, as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ESCAPE trial evaluated the effectiveness of pulmonary artery catheterization in 433 patients with acute decompensated HF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35223/abstract/27\">",
"       27",
"      </a>",
"      ]. There was no correlation between the cardiac index and either the baseline GFR or worsening kidney function, and increasing the cardiac index did not improve renal function after discharge. Similar findings were noted in another report in which HF patients with worsening kidney function did not have lower cardiac outputs or filling pressures than those without worsening kidney function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35223/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      It has been suggested that, although reductions in cardiac index lead to a reduction in renal blood flow, the GFR is initially maintained by an increase in the fraction of renal plasma flow that is filtered (ie, the filtration fraction) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35223/abstract/28\">",
"       28",
"      </a>",
"      ]. In this study, the GFR was similar in patients with a cardiac index of more than 2.0 and 1.5 to 2.0",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      per m2 (respective filtration fractions 24 and 35 percent) but substantially reduced in patients with a cardiac index below 1.5",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      per m2 (38 versus 62 and 67",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, hypotension, which can reduce the GFR independent of renal blood flow, is an uncommon finding in patients hospitalized for acute decompensated HF. In the ADHERE registry of over 100,000 such patients, 50 percent had a systolic blood pressure of 140 mmHg or higher, while less than 2 percent had a systolic blood pressure below 90",
"    <span class=\"nowrap\">",
"     mm/Hg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35223/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2022699\">",
"    <span class=\"h2\">",
"     Increased renal venous pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both animal and human studies have shown that increasing intraabdominal or central venous pressure, which should also increase renal venous pressure, reduce the glomerular filtration rate (GFR) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35223/abstract/4,29\">",
"     4,29",
"    </a>",
"    ]. In an initial study in 17 normal adults, for example, raising the intraabdominal venous pressure to about 20 mmHg led to average reductions in renal plasma flow and GFR of 24 and 28 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35223/abstract/30\">",
"     30",
"    </a>",
"    ]. An adverse impact of venous congestion on kidney function has also been described in animal models as manifested by a reduction in GFR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35223/abstract/31-34\">",
"     31-34",
"    </a>",
"    ] and sodium retention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35223/abstract/31,35,36\">",
"     31,35,36",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Subsequent studies in patients with HF demonstrated an inverse relationship between venous pressure and GFR when the central venous pressure was measured directly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35223/abstract/37-39\">",
"     37-39",
"    </a>",
"    ] or elevated jugular venous pressure was diagnosed on physical examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35223/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, 58 of 145 patients (40 percent) hospitalized for acute decompensated HF developed worsening kidney function, defined as an increase in serum creatinine of at least 0.3",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (27",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35223/abstract/37\">",
"       37",
"      </a>",
"      ]. These patients had a significantly higher central venous pressure (CVP) than those with stable renal function (18 versus 12 mmHg) and the frequency of worsening kidney function was lowest in patients with a CVP less than 8 mmHg. The predictive value of CVP was independent of systemic blood pressure, pulmonary capillary wedge pressure, cardiac index, and estimated GFR. In contrast to the importance of CVP, the cardiac index on admission and an improvement in cardiac index with therapy had a limited impact on the frequency of worsening kidney function.",
"     </li>",
"     <li>",
"      Similar findings were noted in another study in which a higher CVP was also associated with a significant increase in mortality at a median follow-up of more than 10 years (hazard ratio 1.03 per 1 mmHg increase in CVP) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35223/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series of 40 consecutive patients with acute decompensated HF, 24 had an elevation in intraabdominal venous pressure (IAVP) which was defined as 8 mmHg or higher [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35223/abstract/39\">",
"       39",
"      </a>",
"      ]. At baseline, these patients, compared with those with a normal IAVP, had a significantly higher serum creatinine (mean 2.3 versus 1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [203 versus 133",
"      <span class=\"nowrap\">",
"       micromol/L])",
"      </span>",
"      and a significantly lower estimated GFR (mean 40 versus 63",
"      <span class=\"nowrap\">",
"       mL/min).",
"      </span>",
"      In addition, there was a strong correlation between the degree of reduction in IAVP with therapy and improvement in GFR that did not correlate with any other hemodynamic variable (",
"      <a class=\"graphic graphic_figure graphicRef52087 \" href=\"mobipreview.htm?15/16/15629\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Increases in renal venous pressure may also contribute to the association between the degree of tricuspid regurgitation (TR) and worsening kidney function. In a review of 196 patients with TR, those with at least moderate TR had a lower estimated GFR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35223/abstract/41\">",
"     41",
"    </a>",
"    ]. In addition, there was a linear relationship between the severity of TR and the magnitude of impairment in GFR.",
"   </p>",
"   <p>",
"    The mechanisms by which increased renal venous pressure might lead to a reduction in GFR are not well understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35223/abstract/16,29\">",
"     16,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H124107751\">",
"    <span class=\"h2\">",
"     Right ventricular dilatation and dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Right ventricular (RV) dilatation and dysfunction may adversely affect kidney function through at least two mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The associated elevation in central venous pressure elevation can lower the GFR as discussed in the preceding section.",
"     </li>",
"     <li>",
"      RV dilatation impairs left ventricular (LV) filling, and therefore forward output, via a ventricular interdependent effect (also known as the reverse Bernheim phenomenon) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35223/abstract/42\">",
"       42",
"      </a>",
"      ]. Increased pressure within a distended right ventricle increases LV extramural pressure, reducing LV transmural pressure for any given intracavitary LV pressure and inducing leftward interventricular septal bowing, thereby diminishing LV preload and distensibility and reducing forward flow [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35223/abstract/43,44\">",
"       43,44",
"      </a>",
"      ]. An intact pericardium plays a role in ventricular interaction, but experimental observations suggest that the pericardium is not critical to the interaction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35223/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, a reduction in RV filling pressure during treatment of HF may lead to an increase in GFR, both by reducing renal venous pressure and by diminishing ventricular interdependent impairment of left ventricular filling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35223/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10531887\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute or chronic dysfunction of the heart or kidneys can induce acute or chronic dysfunction in the other organ. In addition, both heart and kidney function can be impaired by an acute or chronic systemic disorder. The term cardiorenal syndrome (CRS) has been applied to these interactions. In type 1 CRS, acute heart failure (HF) leads to worsening kidney function. In type 2 CRS, chronic HF causes progressive chronic kidney disease. (See",
"      <a class=\"local\" href=\"#H2022629\">",
"       'Definition and classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevalence of moderate to severe kidney impairment (defined as a glomerular filtration rate [GFR] less than 60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2) is approximately 30 to 40 percent in patients with HF. In addition to these baseline observations, patients undergoing treatment for acute or chronic HF frequently develop an increase in serum creatinine, which fulfills criteria for type 1 or type 2 CRS. (See",
"      <a class=\"local\" href=\"#H61342639\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with HF who have an elevated serum creatinine",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a reduced estimated GFR, it is important to distinguish between underlying kidney disease and impaired kidney function due to the CRS. (See",
"      <a class=\"local\" href=\"#H2022657\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of factors can contribute to a reduction in GFR in patients with HF. The major mechanisms that have been evaluated include neurohumoral adaptations, reduced renal perfusion, increased renal venous pressure, and right ventricular dysfunction. (See",
"      <a class=\"local\" href=\"#H49850194\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     United States Renal Data System: Excerpts from the USRDS 2007 annual data report: atlas of end-stage renal disease in the United States. Minneapolis, MN 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/2\">",
"      Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41:1.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.nhlbi.nih.gov/meetings/workshops/cardiorenal-hf-hd.htm (Accessed on September 01, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/4\">",
"      Bock JS, Gottlieb SS. Cardiorenal syndrome: new perspectives. Circulation 2010; 121:2592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/5\">",
"      Ronco C, Haapio M, House AA, et al. Cardiorenal syndrome. J Am Coll Cardiol 2008; 52:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/6\">",
"      Smith GL, Lichtman JH, Bracken MB, et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 2006; 47:1987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/7\">",
"      Ezekowitz J, McAlister FA, Humphries KH, et al. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol 2004; 44:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/8\">",
"      Hillege HL, Girbes AR, de Kam PJ, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000; 102:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/9\">",
"      Adams KF Jr, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005; 149:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/10\">",
"      Heywood JT, Fonarow GC, Costanzo MR, et al. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail 2007; 13:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/11\">",
"      Owan TE, Hodge DO, Herges RM, et al. Secular trends in renal dysfunction and outcomes in hospitalized heart failure patients. J Card Fail 2006; 12:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/12\">",
"      Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004; 43:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/13\">",
"      Krumholz HM, Chen YT, Vaccarino V, et al. Correlates and impact on outcomes of worsening renal function in patients &gt; or =65 years of age with heart failure. Am J Cardiol 2000; 85:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/14\">",
"      Smith GL, Vaccarino V, Kosiborod M, et al. Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? J Card Fail 2003; 9:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/15\">",
"      Weinfeld MS, Chertow GM, Stevenson LW. Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am Heart J 1999; 138:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/16\">",
"      Shamseddin MK, Parfrey PS. Mechanisms of the cardiorenal syndromes. Nat Rev Nephrol 2009; 5:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/17\">",
"      Cowie MR, Komajda M, Murray-Thomas T, et al. Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH). Eur Heart J 2006; 27:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/18\">",
"      Damman K, Navis G, Voors AA, et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail 2007; 13:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/19\">",
"      Gottlieb SS, Abraham W, Butler J, et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail 2002; 8:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/20\">",
"      Logeart D, Tabet JY, Hittinger L, et al. Transient worsening of renal function during hospitalization for acute heart failure alters outcome. Int J Cardiol 2008; 127:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/21\">",
"      Butler J, Forman DE, Abraham WT, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004; 147:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/22\">",
"      Sarraf M, Masoumi A, Schrier RW. Cardiorenal syndrome in acute decompensated heart failure. Clin J Am Soc Nephrol 2009; 4:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/23\">",
"      Liang KV, Williams AW, Greene EL, Redfield MM. Acute decompensated heart failure and the cardiorenal syndrome. Crit Care Med 2008; 36:S75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/24\">",
"      Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999; 341:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/25\">",
"      Cadnapaphornchai MA, Gurevich AK, Weinberger HD, Schrier RW. Pathophysiology of sodium and water retention in heart failure. Cardiology 2001; 96:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/26\">",
"      Stampfer M, Epstein SE, Beiser GD, Braunwald E. Hemodynamic effects of diuresis at rest and during intense upright exercise in patients with impaired cardiac function. Circulation 1968; 37:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/27\">",
"      Nohria A, Hasselblad V, Stebbins A, et al. Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol 2008; 51:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/28\">",
"      Ljungman S, Laragh JH, Cody RJ. Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function. Drugs 1990; 39 Suppl 4:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/29\">",
"      Wencker D. Acute cardio-renal syndrome: progression from congestive heart failure to congestive kidney failure. Curr Heart Fail Rep 2007; 4:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/30\">",
"      Bradley SE, Bradley GP. THE EFFECT OF INCREASED INTRA-ABDOMINAL PRESSURE ON RENAL FUNCTION IN MAN. J Clin Invest 1947; 26:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/31\">",
"      BLAKE WD, WEGRIA R. Effect of increased renal venous pressure on renal function. Am J Physiol 1949; 157:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/32\">",
"      Burnett JC Jr, Knox FG. Renal interstitial pressure and sodium excretion during renal vein constriction. Am J Physiol 1980; 238:F279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/33\">",
"      Dilley JR, Corradi A, Arendshorst WJ. Glomerular ultrafiltration dynamics during increased renal venous pressure. Am J Physiol 1983; 244:F650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/34\">",
"      Doty JM, Saggi BH, Sugerman HJ, et al. Effect of increased renal venous pressure on renal function. J Trauma 1999; 47:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/35\">",
"      Firth JD, Raine AE, Ledingham JG. Raised venous pressure: a direct cause of renal sodium retention in oedema? Lancet 1988; 1:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/36\">",
"      Abildgaard U, Amtorp O, Holstein-Rathlou NH, et al. Effect of renal venous pressure elevation on tubular sodium and water reabsorption in the dog kidney. Acta Physiol Scand 1988; 132:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/37\">",
"      Mullens W, Abrahams Z, Francis GS, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009; 53:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/38\">",
"      Damman K, van Deursen VM, Navis G, et al. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol 2009; 53:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/39\">",
"      Mullens W, Abrahams Z, Skouri HN, et al. Elevated intra-abdominal pressure in acute decompensated heart failure: a potential contributor to worsening renal function? J Am Coll Cardiol 2008; 51:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/40\">",
"      Drazner MH, Rame JE, Stevenson LW, Dries DL. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med 2001; 345:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/41\">",
"      Maeder MT, Holst DP, Kaye DM. Tricuspid regurgitation contributes to renal dysfunction in patients with heart failure. J Card Fail 2008; 14:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/42\">",
"      Alpert JS. The effect of right ventricular dysfunction on left ventricular form and function. Chest 2001; 119:1632.",
"     </a>",
"    </li>",
"    <li>",
"     Konstam, MA, Isner, J. The Right Ventricle, Konstam, MA, Isner, J (Eds), Kluwer Academic Publishers, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/44\">",
"      Marcus JT, Vonk Noordegraaf A, Roeleveld RJ, et al. Impaired left ventricular filling due to right ventricular pressure overload in primary pulmonary hypertension: noninvasive monitoring using MRI. Chest 2001; 119:1761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/45\">",
"      Little WC, Badke FR, O'Rourke RA. Effect of right ventricular pressure on the end-diastolic left ventricular pressure-volume relationship before and after chronic right ventricular pressure overload in dogs without pericardia. Circ Res 1984; 54:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35223/abstract/46\">",
"      Testani JM, Khera AV, St John Sutton MG, et al. Effect of right ventricular function and venous congestion on cardiorenal interactions during the treatment of decompensated heart failure. Am J Cardiol 2010; 105:511.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13606 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-125.39.66.147-71980919F3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_25_35223=[""].join("\n");
var outline_f34_25_35223=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10531887\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2022629\">",
"      DEFINITION AND CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H61342639\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2022657\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H49850194\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2022664\">",
"      Neurohumoral adaptations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2022685\">",
"      Reduced renal perfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2022699\">",
"      Increased renal venous pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H124107751\">",
"      Right ventricular dilatation and dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10531887\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/13606\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/13606|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/51/11063\" title=\"figure 1\">",
"      CRS Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/56/33677\" title=\"figure 2\">",
"      Frank Starling curves in HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/16/15629\" title=\"figure 3\">",
"      Change in sCr versus change in IAP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16090?source=related_link\">",
"      ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/39/2680?source=related_link\">",
"      Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/26/44456?source=related_link\">",
"      Cardiorenal syndrome: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35785?source=related_link\">",
"      Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23076?source=related_link\">",
"      Pathophysiology of heart failure: Left ventricular pressure-volume relationships",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32455?source=related_link\">",
"      Pathophysiology of heart failure: Neurohumoral adaptations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_25_35224="Influenza and pregnancy";
var content_f34_25_35224=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Influenza and pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/25/35224/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/25/35224/contributors\">",
"     Denise J Jamieson, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/25/35224/contributors\">",
"     Sonja A Rasmussen, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/25/35224/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/25/35224/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/25/35224/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/25/35224/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/25/35224/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/25/35224/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H5795624\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant women with influenza are more likely to develop severe illness and to die than the general population, based on data from seasonal influenza and from the influenza pandemics of 1918-1919, 1957-1958, and 2009-2010. The increased severity of influenza in pregnancy is believed to be related to physiologic changes in pregnancy. For example, changes to the cardiovascular and respiratory systems result in increased heart rate and oxygen consumption and decreased lung capacity, and immunologic alterations result in a shift away from cell-mediated immunity. Because of the increased severity of influenza in pregnancy,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/61/985?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    is recommended for pregnant women, regardless of trimester of pregnancy. In addition, pregnant women with suspected or confirmed influenza should receive prompt empiric treatment with an appropriate antiviral medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5795631\">",
"    <span class=\"h1\">",
"     CLINICAL COURSE IN PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant women are more severely affected by influenza compared with the general population:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During the 1918-1919 and 1957-1958 pandemics, pregnant women had high mortality rates [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/1-4\">",
"       1-4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      During the 2009 H1N1 pandemic, a disproportionate number of deaths occurred among pregnant women, with pregnant women accounting for 5 percent of all deaths, even though pregnant women account for only 1 percent of the US general population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/5\">",
"       5",
"      </a>",
"      ]. Pregnant women were also more likely to be hospitalized during the 2009 H1N1 pandemic than the general population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/6\">",
"       6",
"      </a>",
"      ]; large case series of critically ill pregnant patients were reported from the US [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/5,7,8\">",
"       5,7,8",
"      </a>",
"      ] and other countries [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/9-12\">",
"       9-12",
"      </a>",
"      ]. Although pregnant women were more severely affected once infected, there was no evidence that pregnant women were more susceptible to infection with 2009 H1N1 influenza virus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pregnant women have increased rates of hospitalization for acute respiratory disease during influenza seasons compared to nonpregnant women, which supports increased severity of seasonal influenza during pregnancy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. However, due to low rates of diagnostic testing, studies with confirmed cases of seasonal influenza comparing pregnant and nonpregnant women are lacking.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5795638\">",
"    <span class=\"h2\">",
"     Fetal effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effects of influenza during pregnancy on the embryo or fetus have not been well-studied. Transplacental transmission of influenza virus appears to be rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/16\">",
"     16",
"    </a>",
"    ], but has been documented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/17\">",
"     17",
"    </a>",
"    ]. However, even in the absence of transplacental transmission, influenza during pregnancy might have adverse effects on the fetus.",
"   </p>",
"   <p>",
"    Some studies have suggested that influenza during pregnancy increases the risk for congenital abnormalities such as cleft lip, neural tube defects, and congenital heart defects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. In addition, hyperthermia (including fever) is a risk factor for certain birth defects and other adverse infant outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/20\">",
"     20",
"    </a>",
"    ], and this risk appears to be attenuated by use of antipyretics. Thus, treatment of fever in pregnant women with confirmed or suspected influenza is recommended, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    is the best treatment option during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/13/7386?source=see_link&amp;anchor=H29#H29\">",
"     \"Genetic and environmental causes of birth defects\", section on 'Fever/hyperthermia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/1/42010?source=see_link&amp;anchor=H27#H27\">",
"     \"Initial prenatal assessment and patient education\", section on 'Medications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is also indirect evidence that maternal influenza infection during pregnancy is associated with an increased risk of spontaneous abortion, preterm delivery, low birth weight, birth of a small-for-gestational age infant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/3,6,22-27\">",
"     3,6,22-27",
"    </a>",
"    ], and fetal death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no published guidelines for monitoring the fetus during or after maternal influenza infection. The type and frequency of fetal surveillance should be guided by the healthcare provider&rsquo;s judgment on a case by case basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5795645\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations of influenza among pregnant women are similar to those among the general population, and include fever, cough, rhinorrhea, sore throat, headache, shortness of breath, and myalgia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/13\">",
"     13",
"    </a>",
"    ]. Currently available rapid influenza diagnostic tests do not have sufficient sensitivity to reliably rule out influenza virus infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/28\">",
"     28",
"    </a>",
"    ]. Tests with higher sensitivity (ie, real-time reverse transcriptase polymerase chain reaction) are available, but take more time. Since it is critical in pregnant women to initiate appropriate treatment promptly, the diagnosis of influenza should be made clinically, without waiting for results from diagnostic testing. Recommendations for influenza testing of pregnant women should be consistent with those for other high-risk patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/1/18456?source=see_link\">",
"     \"Clinical manifestations of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37305?source=see_link\">",
"     \"Clinical manifestations and diagnosis of pandemic H1N1 influenza ('swine influenza')\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/25/5528?source=see_link\">",
"     \"Diagnosis of seasonal influenza in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5795652\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5795661\">",
"    <span class=\"h2\">",
"     Vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Influenza vaccination during pregnancy plays a key role in reducing the risk of maternal influenza illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/27,29\">",
"     27,29",
"    </a>",
"    ]. As an example, during the 2009 influenza A (H1N1) pandemic in Norway, vaccination during pregnancy substantially reduced the risk of an influenza diagnosis (adjusted hazard ratio 0.30; 95% CI 0.25-0.34) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/27\">",
"     27",
"    </a>",
"    ]. Although there may be some differences in the antibody response of pregnant women to influenza vaccine compared to nonpregnant women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/30\">",
"     30",
"    </a>",
"    ], pregnant women achieve seroprotection at similar rates to nonpregnant women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/27,29\">",
"     27,29",
"    </a>",
"    ]. Clinical studies and surveillance data have demonstrated the benefits of influenza vaccination for pregnant women, and for their fetuses and infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/27,31\">",
"     27,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vaccination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/61/985?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    has been recommended for pregnant women since the 1960s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/32\">",
"     32",
"    </a>",
"    ]. Since 2004, the US Centers for Disease Control&rsquo;s (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended that all women who are pregnant or will be pregnant during influenza season receive the trivalent inactivated vaccine, regardless of trimester [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/33\">",
"     33",
"    </a>",
"    ]. Despite these recommendations, which are supported and promoted by key professional groups such as the American College of Obstetricians and Gynecologists (ACOG), coverage rates remained low for many years. In response to the 2009 H1N1 pandemic and broad educational efforts to target pregnant women and their providers, national estimates of influenza coverage rates for pregnant women have increased to approximately 40 to 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. In the United States, rates of influenza vaccination during pregnancy are higher in women whose providers specifically recommend it [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/37\">",
"     37",
"    </a>",
"    ]. Furthermore, among providers who recommend the vaccine, vaccination rates are further increased by offering the vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/35\">",
"     35",
"    </a>",
"    ]. These findings highlight the importance of provider involvement to increase influenza vaccination of pregnant women.",
"   </p>",
"   <p>",
"    In addition to protecting the pregnant woman, influenza vaccination during pregnancy provides protection to the infant for up to six months after birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/31,38-40\">",
"     31,38-40",
"    </a>",
"    ]. Infants are at increased risk for severe influenza illness and are not eligible for vaccination until 6 months of age because they fail to mount an adequate immune response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Therefore, vaccination during pregnancy is an important strategy to reduce morbidity and mortality among infants &lt;6 months of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/33\">",
"     33",
"    </a>",
"    ]. There are also data suggesting that influenza vaccination during pregnancy reduces the risk of small-for-gestational age infants, preterm delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/31,43-45\">",
"     31,43-45",
"    </a>",
"    ] and fetal death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/27,45\">",
"     27,45",
"    </a>",
"    ], and increases birth weight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4917167\">",
"    <span class=\"h3\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although pregnant women often have concerns about the safety of vaccines for their fetuses, no studies have shown an increased risk of complications associated with administration of inactivated influenza vaccines to pregnant women compared with the general population. Although rare, all vaccines, including influenza vaccine, have some background risk of adverse effects, such as Guillain-Barre syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40038?source=see_link&amp;anchor=H9#H9\">",
"     \"Pathogenesis of Guillain-Barr&eacute; syndrome in adults\", section on 'Vaccination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/44/41670?source=see_link&amp;anchor=H8#H8\">",
"     \"Approach to immunizations in healthy adults\", section on 'Safety'",
"    </a>",
"    .) However, no specific concerns for pregnant women, their fetuses, or infants have been identified from multiple research studies and monitoring systems worldwide that have collected information on the safety of influenza vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/27,31,47-52\">",
"     27,31,47-52",
"    </a>",
"    ]. Although influenza vaccines that contain adjuvants (substances that boost the immune response and potentially provide longer-lasting and broader protection against antigenically-drifted viruses) have not been widely used in the United States, experience from Europe provides reassuring data on the safety of adjuvant-containing influenza vaccines administered to pregnant women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/53-55\">",
"     53-55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no evidence that vaccines that contain thimerosal are harmful to the children of women who received thimerosal-containing vaccines during pregnancy. However, a thimerosal-free formulation of the trivalent seasonal influenza vaccine is available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/33\">",
"     33",
"    </a>",
"    ]. Pregnant women should not receive live, attenuated vaccine (nasal spray), which is approved only for healthy nonpregnant persons aged 2 to 49, including breastfeeding women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/53/32602?source=see_link\">",
"     \"Immunizations during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5795668\">",
"    <span class=\"h2\">",
"     Antiviral prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decisions regarding antiviral prophylaxis need to take into consideration the host's potential risk of complicated infection and whether the exposure was significant. Antiviral prophylaxis may be considered for pregnant women and women with significant exposures up to two weeks postpartum (including those who have had pregnancy loss), as well as other high risk groups. Early treatment, once signs or symptoms of influenza develop, is an alternative to prophylaxis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44249?source=see_link&amp;anchor=H16#H16\">",
"     \"Prevention of seasonal influenza in adults\", section on 'Definition of high risk'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44249?source=see_link&amp;anchor=H837889#H837889\">",
"     \"Prevention of seasonal influenza in adults\", section on 'Definition of close contact'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     Oseltamivir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    are US FDA Pregnancy Category C drugs, reflecting the lack of clinical studies to assess the safety of their use during pregnancy (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"mobipreview.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ). No adverse events have been shown to be caused by oseltamivir or zanamivir among women who received these agents during pregnancy or among infants who were exposed while in utero [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/21\">",
"     21",
"    </a>",
"    ]. The safety of these drugs in pregnancy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19640?source=see_link&amp;anchor=H14#H14\">",
"     \"Pharmacology of antiviral drugs for influenza\", section on 'Pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     Zanamivir",
"    </a>",
"    may be the drug of choice for prophylaxis in pregnant women, given its limited systemic absorption. However, respiratory complications that may be associated with zanamivir because of its inhaled route of administration need to be considered, especially in women at risk for respiratory problems, such as those with asthma.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     Oseltamivir",
"    </a>",
"    is an alternative agent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19640?source=see_link&amp;anchor=H116594844#H116594844\">",
"     \"Pharmacology of antiviral drugs for influenza\", section on 'Zanamivir'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The dose of influenza antiviral medication recommended for chemoprophylaxis of influenza A and B is [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/56\">",
"     56",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"       Zanamivir",
"      </a>",
"      10 mg (2 inhalations) once daily for up to 10 days, OR",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"       Oseltamivir",
"      </a>",
"      75 mg once daily for up to 10 days",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The recommended duration of prophylaxis is 10 days when administered after a household exposure and 7 days after the most recent exposure in other situations. For control of outbreaks in long-term care facilities and hospitals, the CDC recommends chemoprophylaxis for a minimum of two weeks and up to one week after the most recent known case was identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5795675\">",
"    <span class=\"h2\">",
"     Infection control measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant women with confirmed or suspected influenza infection who present to the hospital for delivery should be placed in a private room and should be cared for using the same infection control precautions for influenza that are used for other patient populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/57\">",
"     57",
"    </a>",
"    ]. Such women should be treated with appropriate antiviral therapy immediately, and treatment should not be delayed while awaiting the results of diagnostic testing (see",
"    <a class=\"local\" href=\"#H5795712\">",
"     'Antiviral medications'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/34/2599?source=see_link\">",
"     \"Infection control measures to prevent seasonal influenza in healthcare settings\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In outpatient settings, patients should be screened for respiratory symptoms and triaged appropriately. For example, when scheduling appointments, patients and persons who accompany them can be instructed to inform office staff if they have symptoms of a respiratory infection such as cough, runny nose, or fever. In addition, at time of check-in, patients can be asked about the presence of symptoms. For symptomatic patients, facemasks should be provided, as well as supplies and instructions to perform hand hygiene. Separate waiting areas may be provided for persons with symptoms of a respiratory infection",
"    <span class=\"nowrap\">",
"     (file://www.cdc.gov/flu/professionals/infectioncontrol/healthcaresettings.htm).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5795682\">",
"    <span class=\"h2\">",
"     Healthy term newborns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Healthy term newborns of mothers with confirmed or suspected influenza infection should be considered exposed, not infected, if they are born in the hospital using the recommended infection control guidelines. Given the risk of severe complications of influenza in newborns, the CDC recommends that temporary separation of a mother with suspected or confirmed influenza from her newborn be considered. The length of temporary separation needs to be made on a case-by-case basis. Although there are no data on which to formulate evidence-based recommendations about the length of separation, guidelines developed during the 2009 H1N1 pandemic may provide a reasonable approach. CDC guidelines during the 2009 H1N1 pandemic recommended that a mother with 2009 H1N1 be separated from her infant until three criteria were met: the mother had received antiviral medications for 48 hours, was afebrile without antipyretics for &gt;24 hours, and was able to control her cough and respiratory secretions. Asymptomatic healthy term newborns can be cared for in the well-born nursery using Standard Precautions and should be observed for signs of infection.",
"   </p>",
"   <p>",
"    If temporary separation is not feasible or acceptable, then engineering controls should be considered, such as physical barriers, keeping the newborn &gt;6 feet away from the ill mother, and ensuring that a healthy adult cares for the newborn.",
"   </p>",
"   <p>",
"    During temporary separation, all feedings should be provided by a healthy caregiver. Mothers who intend to breastfeed should be encouraged to express their milk (see",
"    <a class=\"local\" href=\"#H5795689\">",
"     'Breastfeeding'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    All individuals who live with, or provide care for, infants younger than 6 months of age should be vaccinated against influenza. Before discharge, influenza vaccination status of all household contacts and caregivers of the newborn should be assessed and those who are unvaccinated and eligible for vaccination (ie, &gt;6 months of age) should be strongly encouraged to be vaccinated. When possible, vaccination for caregivers and household contacts should be provided before the infant is discharged home from the hospital [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5795689\">",
"    <span class=\"h2\">",
"     Breastfeeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;During temporary separation, mothers who intend to breastfeed should be encouraged to express their breast milk, which a healthy caregiver can use to bottle feed the newborn. Although data on the safety of antiviral medications during lactation are limited, use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    by breastfeeding mothers appears to pose no harm to their infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. We are not aware of any studies on the safety of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    during breastfeeding. Thus, women with suspected or confirmed influenza who are breastfeeding should be encouraged to continue breastfeeding if possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5795696\">",
"    <span class=\"h2\">",
"     Pregnant healthcare workers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although pregnant healthcare workers should observe the same infection control procedures as all healthcare personnel, they may be offered some accommodations (eg, avoiding involvement with aerosol-generating procedures on patients with suspected or confirmed influenza) to avoid potentially high-risk exposures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5795703\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5795712\">",
"    <span class=\"h2\">",
"     Antiviral medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Healthcare providers should educate pregnant women about influenza symptoms and the need to contact their healthcare provider promptly to avoid delay in treatment. (See",
"    <a class=\"local\" href=\"#H5795645\">",
"     'Clinical manifestations and diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Pregnant women with suspected influenza should receive prompt empiric treatment with appropriate influenza antiviral medications since available data suggest that the benefits outweigh the theoretical risk to the fetus. Treatment decisions, especially those involving empiric treatments, should be informed by knowledge of influenza activity in the community. Studies from the 2009-2010 season demonstrated that initiating treatment of pregnant women early (generally &lt;2 days) from onset of influenza symptoms was associated with less severe disease and fewer deaths compared with treatment begun later [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/5,7,22,61,62\">",
"     5,7,22,61,62",
"    </a>",
"    ]. Data also suggest a benefit of treatment even if treatment is initiated more than two days after symptom onset. Therefore, treatment should be initiated as soon as possible, even if more than two days after symptom onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/61\">",
"     61",
"    </a>",
"    ]. Particularly in severely ill pregnant women, treatment should be initiated regardless of the time since symptom onset as the risk of treatment is believed to be low and there may be some benefit even after a prolonged delay.",
"   </p>",
"   <p>",
"    Women who are up to two weeks postpartum, including following pregnancy loss, should also receive prompt empiric treatment. This recommendation is based on surveillance data from California in which nine postpartum women with 2009 H1N1 infection were admitted to the intensive care unit; three of whom died. Eight of the nine women, including all three who died, had symptom onset eight days or less after delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since 2009, the majority of influenza viruses identified have been susceptible to the neuraminidase inhibitors,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    (updated resistance information can be found at",
"    <span class=\"nowrap\">",
"     www.cdc.gov/flu).",
"    </span>",
"    In the United States, oseltamivir and zanamivir are Pregnancy Category C drugs (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"mobipreview.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ), reflecting the lack of clinical studies to assess the safety of their use during pregnancy. However, there is no evidence suggesting increased fetal risk following prenatal exposure to influenza antiviral medications, although the numbers of first trimester exposures have been small [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/61,64-67\">",
"     61,64-67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19640?source=see_link&amp;anchor=H14#H14\">",
"     \"Pharmacology of antiviral drugs for influenza\", section on 'Pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For treatment of pregnant women,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    is generally preferred over inhaled",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    , assuming that prevalence of oseltamivir resistance is low among circulating influenza viruses. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/60/39880?source=see_link\">",
"     \"Antiviral drug resistance among seasonal influenza viruses\"",
"    </a>",
"    .) Oseltamivir is preferred for treatment because of its systemic absorption and the greater clinical experience using this drug in pregnancy. Although the drug of choice is less clear for prophylaxis, zanamivir may be preferable, given its limited bioavailability. However, respiratory complications that may be associated with zanamivir because of its inhaled route of administration need to be considered, especially in women at risk for respiratory problems, such as asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the influenza vaccine is not 100 percent effective and infection after vaccination has been documented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/68\">",
"     68",
"    </a>",
"    ], pregnant women with suspected influenza infection should be treated promptly regardless of vaccination status. Based on limited data, the dosing of antiviral therapy for treatment of influenza A and B during pregnancy is the same as in nonpregnant adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/56\">",
"     56",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"       Oseltamivir",
"      </a>",
"      75 mg twice daily for five days, OR",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"       Zanamivir",
"      </a>",
"      10 mg (2 inhalations) for five days",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Longer treatment courses can be considered for patients who remain severely ill after five days of treatment. Some clinicians have recommended that severely ill patients be treated with double-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    (ie, 150 mg twice daily); however, no data are available to suggest that higher doses are more effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/69\">",
"     69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22250?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of seasonal influenza in adults\", section on 'Neuraminidase inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early treatment can be facilitated by healthcare providers in several ways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/70\">",
"     70",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inform pregnant and postpartum women about signs and symptoms of influenza and the need to contact their healthcare provider for early treatment",
"     </li>",
"     <li>",
"      Ensure rapid access to telephone consultation and clinical evaluation, and",
"     </li>",
"     <li>",
"      Consider empiric treatment based on telephone consultation if this will substantially reduce delay before treatment initiation (assuming that hospitalization is not indicated).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5795719\">",
"    <span class=\"h2\">",
"     Intravenous therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the 2009-2010 season, some critically ill pregnant patients with 2009 H1N1 infection were treated with intravenous neuraminidase inhibitors; peramivir and the intravenous formulation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    are investigational. Data on the effects of these medications on maternal or fetal outcomes are not available. The oral formulation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    appears to be adequately absorbed following nasogastric administration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22250?source=see_link&amp;anchor=H23#H23\">",
"     \"Treatment of seasonal influenza in adults\", section on 'Investigational approaches'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/21/38234?source=see_link&amp;anchor=H414876#H414876\">",
"     \"Treatment and prevention of pandemic H1N1 influenza ('swine influenza')\", section on 'Antiviral agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5795726\">",
"    <span class=\"h2\">",
"     Antipyretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to antiviral therapy, use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    is important when fever is present, since hyperthermia during the first trimester has been associated with neural tube defects and possibly other birth defects. In addition, fever during labor is a risk factor for neonatal seizures, encephalopathy, cerebral palsy, and neonatal death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/20,71,72\">",
"     20,71,72",
"    </a>",
"    ]. Although prenatal use of acetaminophen has been associated with asthma in some but not all studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/73-75\">",
"     73-75",
"    </a>",
"    ], other antipyretics (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ) have been associated with adverse pregnancy and infant outcomes. Therefore, acetaminophen appears to be the best option for treatment of fever in pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35224/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5795733\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnant women with influenza are at increased risk for serious complications, requiring hospitalization and intensive care unit care, and death. (See",
"      <a class=\"local\" href=\"#H5795631\">",
"       'Clinical course in pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of influenza should be made clinically, without waiting for results from diagnostic testing. Rapid influenza diagnostic tests have low sensitivity for circulating viruses. Tests with higher sensitivity (ie, real-time reverse transcriptase polymerase chain reaction) are available, but initiation of treatment should not be delayed while waiting for these results. (See",
"      <a class=\"local\" href=\"#H5795645\">",
"       'Clinical manifestations and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infection control measures are indicated in outpatient and inpatient settings to reduce the risk for transmission of virus among mothers, newborns, staff and nonstaff in contact with mothers and newborns. (See",
"      <a class=\"local\" href=\"#H5795675\">",
"       'Infection control measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All women who are pregnant or will be pregnant during influenza season should receive the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/61/985?source=see_link\">",
"       inactivated influenza vaccine",
"      </a>",
"      , regardless of pregnancy trimester (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5795661\">",
"       'Vaccination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chemoprophylaxis with an antiviral medication can be considered for pregnant women with a significant exposure to a person with influenza. Early treatment is an alternative to prophylaxis.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"       Zanamivir",
"      </a>",
"      may be the drug of choice for prophylaxis in pregnant women (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Prompt antiviral treatment is recommended for pregnant and postpartum (at least two weeks following delivery, regardless of the length of pregnancy) women with confirmed or suspected influenza (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Early treatment (within two days of symptom onset) was associated with a lower risk for admission to an intensive care unit and death, when compared with treatment initiated later. However, beginning treatment &gt;2 days after symptom onset also has benefits. (See",
"      <a class=\"local\" href=\"#H5795703\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/1\">",
"      FREEMAN DW, BARNO A. Deaths from Asian influenza associated with pregnancy. Am J Obstet Gynecol 1959; 78:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/2\">",
"      HARDY JM, AZAROWICZ EN, MANNINI A, et al. The effect of Asian influenza on the outcome of pregnancy, Baltimore, 1957-1958. Am J Public Health Nations Health 1961; 51:1182.",
"     </a>",
"    </li>",
"    <li>",
"     Harris, JW. Influenza occurring in pregnant women. JAMA 1919; 72:978.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/4\">",
"      Nuzum JW, Pilot I, Stangl FH, Bonar BE. 1918 pandemic influenza and pneumonia in a large civil hospital. IMJ Ill Med J 1976; 150:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/5\">",
"      Siston AM, Rasmussen SA, Honein MA, et al. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA 2010; 303:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/6\">",
"      Mosby LG, Rasmussen SA, Jamieson DJ. 2009 pandemic influenza A (H1N1) in pregnancy: a systematic review of the literature. Am J Obstet Gynecol 2011; 205:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/7\">",
"      Louie JK, Acosta M, Jamieson DJ, et al. Severe 2009 H1N1 influenza in pregnant and postpartum women in California. N Engl J Med 2010; 362:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/8\">",
"      Varner MW, Rice MM, Anderson B, et al. Influenza-like illness in hospitalized pregnant and postpartum women during the 2009-2010 H1N1 pandemic. Obstet Gynecol 2011; 118:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/9\">",
"      ANZIC Influenza Investigators and Australasian Maternity Outcomes Surveillance System. Critical illness due to 2009 A/H1N1 influenza in pregnant and postpartum women: population based cohort study. BMJ 2010; 340:c1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/10\">",
"      Hewagama S, Walker SP, Stuart RL, et al. 2009 H1N1 influenza A and pregnancy outcomes in Victoria, Australia. Clin Infect Dis 2010; 50:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/11\">",
"      Campbell A, Rodin R, Kropp R, et al. Risk of severe outcomes among patients admitted to hospital with pandemic (H1N1) influenza. CMAJ 2010; 182:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/12\">",
"      Kumar A, Zarychanski R, Pinto R, et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 2009; 302:1872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/13\">",
"      Jamieson DJ, Honein MA, Rasmussen SA, et al. H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet 2009; 374:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/14\">",
"      Dodds L, McNeil SA, Fell DB, et al. Impact of influenza exposure on rates of hospital admissions and physician visits because of respiratory illness among pregnant women. CMAJ 2007; 176:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/15\">",
"      Neuzil KM, Reed GW, Mitchel EF, et al. Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. Am J Epidemiol 1998; 148:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/16\">",
"      Irving WL, James DK, Stephenson T, et al. Influenza virus infection in the second and third trimesters of pregnancy: a clinical and seroepidemiological study. BJOG 2000; 107:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/17\">",
"      Gu J, Xie Z, Gao Z, et al. H5N1 infection of the respiratory tract and beyond: a molecular pathology study. Lancet 2007; 370:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/18\">",
"      Acs N, B&aacute;nhidy F, Puh&oacute; E, Czeizel AE. Maternal influenza during pregnancy and risk of congenital abnormalities in offspring. Birth Defects Res A Clin Mol Teratol 2005; 73:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/19\">",
"      Rasmussen SA, Jamieson DJ, Bresee JS. Pandemic influenza and pregnant women. Emerg Infect Dis 2008; 14:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/20\">",
"      Moretti ME, Bar-Oz B, Fried S, Koren G. Maternal hyperthermia and the risk for neural tube defects in offspring: systematic review and meta-analysis. Epidemiology 2005; 16:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/21\">",
"      Rasmussen SA, Kissin DM, Yeung LF, et al. Preparing for influenza after 2009 H1N1: special considerations for pregnant women and newborns. Am J Obstet Gynecol 2011; 204:S13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/22\">",
"      Centers for Disease Control and Prevention (CDC). Maternal and infant outcomes among severely ill pregnant and postpartum women with 2009 pandemic influenza A (H1N1)--United States, April 2009-August 2010. MMWR Morb Mortal Wkly Rep 2011; 60:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/23\">",
"      Bloom-Feshbach K, Simonsen L, Viboud C, et al. Natality decline and miscarriages associated with the 1918 influenza pandemic: the Scandinavian and United States experiences. J Infect Dis 2011; 204:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/24\">",
"      McNeil SA, Dodds LA, Fell DB, et al. Effect of respiratory hospitalization during pregnancy on infant outcomes. Am J Obstet Gynecol 2011; 204:S54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/25\">",
"      Mendez-Figueroa H, Raker C, Anderson BL. Neonatal characteristics and outcomes of pregnancies complicated by influenza infection during the 2009 pandemic. Am J Obstet Gynecol 2011; 204:S58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/26\">",
"      Yates L, Pierce M, Stephens S, et al. Influenza A/H1N1v in pregnancy: an investigation of the characteristics and management of affected women and the relationship to pregnancy outcomes for mother and infant. Health Technol Assess 2010; 14:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/27\">",
"      H&aring;berg SE, Trogstad L, Gunnes N, et al. Risk of fetal death after pandemic influenza virus infection or vaccination. N Engl J Med 2013; 368:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/28\">",
"      Centers for Disease Control and Prevention (CDC). Evaluation of rapid influenza diagnostic tests for influenza A (H3N2)v virus and updated case count--United States, 2012. MMWR Morb Mortal Wkly Rep 2012; 61:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/29\">",
"      Jamieson DJ, Kissin DM, Bridges CB, Rasmussen SA. Benefits of influenza vaccination during pregnancy for pregnant women. Am J Obstet Gynecol 2012; 207:S17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/30\">",
"      Schlaudecker EP, McNeal MM, Dodd CN, et al. Pregnancy modifies the antibody response to trivalent influenza immunization. J Infect Dis 2012; 206:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/31\">",
"      Zaman K, Roy E, Arifeen SE, et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008; 359:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/32\">",
"      Burney LE. Influenza immunization: Statement. Public Health Rep 1960; 75:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/33\">",
"      Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/34\">",
"      Centers for Disease Control and Prevention (CDC). Influenza vaccination coverage among pregnant women --- United States, 2010-11 influenza season. MMWR Morb Mortal Wkly Rep 2011; 60:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/35\">",
"      Centers for Disease Control and Prevention (CDC). Influenza vaccination coverage among pregnant women: 2011-12 influenza season, United States. MMWR Morb Mortal Wkly Rep 2012; 61:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/36\">",
"      Kennedy ED, Ahluwalia IB, Ding H, et al. Monitoring seasonal influenza vaccination coverage among pregnant women in the United States. Am J Obstet Gynecol 2012; 207:S9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/37\">",
"      Centers for Disease Control and Prevention (CDC). Influenza vaccination coverage among pregnant women - 29 States and New York City, 2009-10 season. MMWR Morb Mortal Wkly Rep 2012; 61:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/38\">",
"      Eick AA, Uyeki TM, Klimov A, et al. Maternal influenza vaccination and effect on influenza virus infection in young infants. Arch Pediatr Adolesc Med 2011; 165:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/39\">",
"      Poehling KA, Szilagyi PG, Staat MA, et al. Impact of maternal immunization on influenza hospitalizations in infants. Am J Obstet Gynecol 2011; 204:S141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/40\">",
"      Benowitz I, Esposito DB, Gracey KD, et al. Influenza vaccine given to pregnant women reduces hospitalization due to influenza in their infants. Clin Infect Dis 2010; 51:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/41\">",
"      Groothuis JR, Levin MJ, Rabalais GP, et al. Immunization of high-risk infants younger than 18 months of age with split-product influenza vaccine. Pediatrics 1991; 87:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/42\">",
"      Halasa NB, Gerber MA, Chen Q, et al. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants. J Infect Dis 2008; 197:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/43\">",
"      Omer SB, Goodman D, Steinhoff MC, et al. Maternal influenza immunization and reduced likelihood of prematurity and small for gestational age births: a retrospective cohort study. PLoS Med 2011; 8:e1000441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/44\">",
"      Steinhoff MC, Omer SB, Roy E, et al. Neonatal outcomes after influenza immunization during pregnancy: a randomized controlled trial. CMAJ 2012; 184:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/45\">",
"      Fell DB, Sprague AE, Liu N, et al. H1N1 influenza vaccination during pregnancy and fetal and neonatal outcomes. Am J Public Health 2012; 102:e33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/46\">",
"      De Wals P, Deceuninck G, Toth E, et al. Risk of Guillain-Barr&eacute; syndrome following H1N1 influenza vaccination in Quebec. JAMA 2012; 308:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/47\">",
"      Tamma PD, Ault KA, del Rio C, et al. Safety of influenza vaccination during pregnancy. Am J Obstet Gynecol 2009; 201:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/48\">",
"      Pasternak B, Svanstr&ouml;m H, M&oslash;lgaard-Nielsen D, et al. Vaccination against pandemic A/H1N1 2009 influenza in pregnancy and risk of fetal death: cohort study in Denmark. BMJ 2012; 344:e2794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/49\">",
"      Pasternak B, Svanstr&ouml;m H, M&oslash;lgaard-Nielsen D, et al. Risk of adverse fetal outcomes following administration of a pandemic influenza A(H1N1) vaccine during pregnancy. JAMA 2012; 308:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/50\">",
"      Sheffield JS, Greer LG, Rogers VL, et al. Effect of influenza vaccination in the first trimester of pregnancy. Obstet Gynecol 2012; 120:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/51\">",
"      Irving SA, Kieke BA, Donahue JG, et al. Trivalent inactivated influenza vaccine and spontaneous abortion. Obstet Gynecol 2013; 121:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/52\">",
"      Nordin JD, Kharbanda EO, Benitez GV, et al. Maternal Safety of Trivalent Inactivated Influenza Vaccine in Pregnant Women. Obstet Gynecol 2013; 121:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/53\">",
"      Jamieson DJ, Rasmussen SA. The safety of adjuvants in influenza vaccines during pregnancy: what do we know and why do we need them? Am J Obstet Gynecol 2012; 207:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/54\">",
"      Heikkinen T, Young J, van Beek E, et al. Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study. Am J Obstet Gynecol 2012; 207:177.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/55\">",
"      K&auml;ll&eacute;n B, Olausson PO. Vaccination against H1N1 influenza with Pandemrix(&reg;) during pregnancy and delivery outcome: a Swedish register study. BJOG 2012; 119:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/56\">",
"      Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     \"Prevention Strategies for Seasonal Influenza in Healthcare Settings.\" file://www.cdc.gov/flu/professionals/infectioncontrol/healthcaresettings.htm (Accessed on October 03, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/58\">",
"      Walter EB, Allred NJ, Swamy GK, et al. Influenza vaccination of household contacts of newborns: a hospital-based strategy to increase vaccination rates. Infect Control Hosp Epidemiol 2010; 31:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/59\">",
"      Wentges-van Holthe N, van Eijkeren M, van der Laan JW. Oseltamivir and breastfeeding. Int J Infect Dis 2008; 12:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/60\">",
"      Greer LG, Leff RD, Rogers VL, et al. Pharmacokinetics of oseltamivir according to trimester of pregnancy. Am J Obstet Gynecol 2011; 204:S89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/61\">",
"      Creanga AA, Johnson TF, Graitcer SB, et al. Severity of 2009 pandemic influenza A (H1N1) virus infection in pregnant women. Obstet Gynecol 2010; 115:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/62\">",
"      Hansen C, Desai S, Bredfeldt C, et al. A large, population-based study of 2009 pandemic Influenza A virus subtype H1N1 infection diagnosis during pregnancy and outcomes for mothers and neonates. J Infect Dis 2012; 206:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/63\">",
"      Louie JK, Jamieson DJ, Rasmussen SA. 2009 pandemic influenza A (H1N1) virus infection in postpartum women in California. Am J Obstet Gynecol 2011; 204:144.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/64\">",
"      Rasmussen SA, Jamieson DJ, Macfarlane K, et al. Pandemic influenza and pregnant women: summary of a meeting of experts. Am J Public Health 2009; 99 Suppl 2:S248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/65\">",
"      Greer LG, Sheffield JS, Rogers VL, et al. Maternal and neonatal outcomes after antepartum treatment of influenza with antiviral medications. Obstet Gynecol 2010; 115:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/66\">",
"      Tanaka T, Nakajima K, Murashima A, et al. Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women. CMAJ 2009; 181:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/67\">",
"      Xie HY, Yasseen AS 3rd, Xie RH, et al. Infant outcomes among pregnant women who used oseltamivir for treatment of influenza during the H1N1 epidemic. Am J Obstet Gynecol 2013; 208:293.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/68\">",
"      Louie JK, Wadford DA, Norman A, Jamieson DJ. 2009 pandemic influenza A (H1N1) and vaccine failure in pregnancy. Obstet Gynecol 2011; 117:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/69\">",
"      Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/flu/professionals/antivirals/avrec_ob2011.htm (Accessed on October 03, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/71\">",
"      Edwards MJ. Review: Hyperthermia and fever during pregnancy. Birth Defects Res A Clin Mol Teratol 2006; 76:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/72\">",
"      Petrova A, Demissie K, Rhoads GG, et al. Association of maternal fever during labor with neonatal and infant morbidity and mortality. Obstet Gynecol 2001; 98:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/73\">",
"      Kang EM, Lundsberg LS, Illuzzi JL, Bracken MB. Prenatal exposure to acetaminophen and asthma in children. Obstet Gynecol 2009; 114:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/74\">",
"      Lowe AJ, Carlin JB, Bennett CM, et al. Paracetamol use in early life and asthma: prospective birth cohort study. BMJ 2010; 341:c4616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35224/abstract/75\">",
"      Rebordosa C, Kogevinas M, S&oslash;rensen HT, Olsen J. Pre-natal exposure to paracetamol and risk of wheezing and asthma in children: a birth cohort study. Int J Epidemiol 2008; 37:583.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15870 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-C08C8C0CB4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_25_35224=[""].join("\n");
var outline_f34_25_35224=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5795733\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5795624\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5795631\">",
"      CLINICAL COURSE IN PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5795638\">",
"      Fetal effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5795645\">",
"      CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5795652\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5795661\">",
"      Vaccination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4917167\">",
"      - Safety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5795668\">",
"      Antiviral prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5795675\">",
"      Infection control measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5795682\">",
"      Healthy term newborns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5795689\">",
"      Breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5795696\">",
"      Pregnant healthcare workers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5795703\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5795712\">",
"      Antiviral medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5795719\">",
"      Intravenous therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5795726\">",
"      Antipyretics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5795733\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/15870\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/15870|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\" title=\"table 1\">",
"      Drug ratings in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/60/39880?source=related_link\">",
"      Antiviral drug resistance among seasonal influenza viruses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/44/41670?source=related_link\">",
"      Approach to immunizations in healthy adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37305?source=related_link\">",
"      Clinical manifestations and diagnosis of pandemic H1N1 influenza ('swine influenza')",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/1/18456?source=related_link\">",
"      Clinical manifestations of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/25/5528?source=related_link\">",
"      Diagnosis of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/13/7386?source=related_link\">",
"      Genetic and environmental causes of birth defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/53/32602?source=related_link\">",
"      Immunizations during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/34/2599?source=related_link\">",
"      Infection control measures to prevent seasonal influenza in healthcare settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/1/42010?source=related_link\">",
"      Initial prenatal assessment and patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40038?source=related_link\">",
"      Pathogenesis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19640?source=related_link\">",
"      Pharmacology of antiviral drugs for influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44249?source=related_link\">",
"      Prevention of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/21/38234?source=related_link\">",
"      Treatment and prevention of pandemic H1N1 influenza ('swine influenza')",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22250?source=related_link\">",
"      Treatment of seasonal influenza in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_25_35225="Clinical manifestations of Lyme disease in adults";
var content_f34_25_35225=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations of Lyme disease in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/25/35225/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/25/35225/contributors\">",
"     Linden Hu, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/25/35225/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/25/35225/contributors\">",
"     Allen C Steere, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/25/35225/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/25/35225/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/25/35225/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lyme disease is a tick-borne illness caused by three pathogenic species of the spirochete Borrelia burgdorferi sensu lato. B. burgdorferi is the sole cause of the disease in the United States. All three pathogenic species, B. burgdorferi, B. afzelii and B. garinii, occur in Europe, and the latter two species have been identified in Asia. Lyme disease has a broad spectrum of clinical manifestations, and it also varies in severity due, in part, to differences in the infecting species.",
"   </p>",
"   <p>",
"    Lyme disease was first described in 1977 as \"Lyme arthritis\" in studies of a cluster in Connecticut of children who were thought to have juvenile rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/1\">",
"     1",
"    </a>",
"    ]. The multisystem nature of the infection became clear as involvement of other systems was subsequently identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations of Lyme disease in adults will be reviewed here. Issues related to bacteriology, epidemiology, diagnosis, and therapy, and more detailed descriptions of the various clinical manifestations of Lyme disease, are discussed separately in the appropriate topic reviews. The clinical manifestations of Lyme disease in children are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/3/7225?source=see_link\">",
"     \"Lyme disease: Clinical manifestations in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other tick-borne diseases are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/51/14135?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Rocky Mountain spotted fever\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/5/6234?source=see_link\">",
"     \"Human ehrlichiosis and anaplasmosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26533?source=see_link\">",
"     \"Southern tick-associated rash illness (STARI)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/25/39321?source=see_link\">",
"     \"Clinical manifestations, diagnosis, treatment, and prevention of babesiosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL STAGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of Lyme disease can generally be divided into three phases: early localized, early disseminated, and late disease (",
"    <a class=\"graphic graphic_table graphicRef72018 \" href=\"mobipreview.htm?39/7/40060\">",
"     table 1",
"    </a>",
"    ). However, the clinical features of each stage can overlap and some patients present in a later stage of Lyme disease without a history of prior signs or symptoms suggestive of earlier Lyme disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early localized disease is characterized by the appearance of the characteristic skin lesion, erythema migrans (EM), with or without constitutional symptoms (",
"      <a class=\"graphic graphic_picture graphicRef81270 \" href=\"mobipreview.htm?10/10/10400\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef57414 \" href=\"mobipreview.htm?0/35/575\">",
"       picture 2",
"      </a>",
"      ). EM usually occurs within one month following the tick bite.",
"     </li>",
"     <li>",
"      Early disseminated disease is characterized by multiple EM lesions (that typically occur days to weeks after infection)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      neurologic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cardiac findings (that typically occur weeks to months after infection). Some of these patients have no history of antecedent early localized Lyme disease.",
"     </li>",
"     <li>",
"      Late Lyme disease is typically associated with intermittent or persistent arthritis involving one or a few large joints, especially the knee (sometimes preceded by migratory arthralgias),",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      certain rare neurologic problems, primarily a subtle encephalopathy or polyneuropathy. Late Lyme disease may develop months to a few years after the initial infection. Arthritis may be the presenting manifestation of the disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     UNITED STATES VERSUS EUROPE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basic features of Lyme disease are similar worldwide, but there are regional variations, primarily between the illness found in the United States and that found in Europe and Asia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/5\">",
"     5",
"    </a>",
"    ]. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective cohort study evaluated 204 patients with erythema migrans (EM), 119 due to B. burgdorferi sensu stricto in the United States and 85 due to B. afzelii in Slovenia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/6\">",
"       6",
"      </a>",
"      ]. American patients had higher rates of systemic symptoms (69 versus 51 percent), multiple EM lesions (13 versus 7 percent), and seropositivity (89 versus 31 percent), and a briefer duration of EM prior to presentation (4 versus 14 days).",
"     </li>",
"     <li>",
"      In another report, EM lesions in American patients who had B. burgdorferi infection expanded faster than lesions in Austrian patients who had B. afzelii infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/7\">",
"       7",
"      </a>",
"      ]. The more rapidly growing EM lesions in American patients was associated with higher mRNA levels of chemokines and cytokines associated with macrophage activation.",
"     </li>",
"     <li>",
"      Some of the skin manifestations of Lyme disease such as borrelial lymphocytoma, acrodermatitis chronica atrophicans, and morphea-like lesions, seem to occur exclusively in Europe. In addition, B. garinii infection in Europe rarely causes the following late neurologic features: chronic encephalomyelitis, characterized by spastic paraparesis, cranial neuropathy, or cognitive impairment with marked intrathecal antibody production to the spirochete. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Borrelial lymphocytoma'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H18\">",
"       'Cutaneous manifestations'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H17\">",
"       'Neurologic features'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EARLY LOCALIZED DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early localized disease includes erythema migrans (EM) and nonspecific findings that resemble a viral syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Erythema migrans",
"    </span>",
"    &nbsp;&mdash;&nbsp;EM is a rash that appears at the site of the tick bite, usually within 7 to 14 days after the bite (range 3 to 30 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/8\">",
"     8",
"    </a>",
"    ]. While early erythema at the tick bite site is common due to a reaction to antigens in the tick saliva, this early allergic reaction must be differentiated from EM, which requires at least several days before slow expansion of the lesion begins. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/35/28216?source=see_link&amp;anchor=H10#H10\">",
"     \"Insect bites\", section on 'Ticks'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    EM occurs in approximately 80 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/9\">",
"     9",
"    </a>",
"    ]. Approximately 25 percent of patients with early, localized Lyme disease recall a tick bite [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    EM lesions typically have the following characteristics (",
"    <a class=\"graphic graphic_picture graphicRef81270 \" href=\"mobipreview.htm?10/10/10400\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef57414 \" href=\"mobipreview.htm?0/35/575\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They are often found in or near the axilla, inguinal region, popliteal fossa, or at the belt line.",
"     </li>",
"     <li>",
"      They are not particularly painful, although EM lesions may occasionally burn or itch, and are hot to the touch.",
"     </li>",
"     <li>",
"      They typically expand slowly over the course of days or weeks, often with central clearing, and may reach a diameter of more than 20 cm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/10,12\">",
"       10,12",
"      </a>",
"      ]. During the first days, EM lesions may be uniformly red. As they expand, some central clearing often develops, and they may have a more complex target or bull's eye appearance.",
"      <br/>",
"      <br/>",
"      Although central clearing is considered classic for EM, it often requires considerable expansion of the lesion and is usually not yet present in the first days of illness. In an observational cohort study of 118 cases of EM in which B. burgdorferi infection was confirmed by culture or polymerase chain reaction (PCR), the EM lesion was homogeneous in 59 percent, had central erythema in 32 percent, and central clearing in 9 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/13\">",
"       13",
"      </a>",
"      ]. The patients sought medical care at a median of three days following the appearance of the rash.",
"     </li>",
"     <li>",
"      EM lesions rarely have necrotic or vesicular centers (",
"      <a class=\"graphic graphic_picture graphicRef67424 \" href=\"mobipreview.htm?34/20/35140\">",
"       picture 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Histologic examination reveals evidence of vascular endothelial cell injury (",
"      <a class=\"graphic graphic_picture graphicRef74443 graphicRef53473 \" href=\"mobipreview.htm?11/47/12026\">",
"       picture 4A-B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Multiple EM lesions are a sign of spirochetemia, not multiple tick bites (",
"    <a class=\"graphic graphic_picture graphicRef75337 \" href=\"mobipreview.htm?26/16/26883\">",
"     picture 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef64784 \" href=\"mobipreview.htm?6/18/6436\">",
"     picture 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/14\">",
"     14",
"    </a>",
"    ]. In a series of 314 patients seen before the etiology of Lyme disease was known, almost one-half developed multiple EM lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/15\">",
"     15",
"    </a>",
"    ]. In contrast, later series in which all patients were treated promptly with antibiotic therapy found multiple EM lesions in only 10 to 18 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/6,10\">",
"     6,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to note that a skin lesion indistinguishable from EM occurs in Southern tick-associated rash illness (STARI), an illness principally found in the southeast and south central regions of the United States (",
"    <a class=\"graphic graphic_picture graphicRef60256 \" href=\"mobipreview.htm?32/19/33086\">",
"     picture 7",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26533?source=see_link\">",
"     \"Southern tick-associated rash illness (STARI)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the first days or weeks of infection, patients with early, localized, or disseminated Lyme disease often also have nonspecific signs and symptoms resembling a viral syndrome. In a prospective study of 79 patients with culture-confirmed EM, common clinical manifestations included the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fatigue - 54 percent",
"     </li>",
"     <li>",
"      Anorexia - 26 percent",
"     </li>",
"     <li>",
"      Headache - 42 percent",
"     </li>",
"     <li>",
"      Neck stiffness - 35 percent",
"     </li>",
"     <li>",
"      Myalgias - 44 percent",
"     </li>",
"     <li>",
"      Arthralgias - 44 percent",
"     </li>",
"     <li>",
"      Regional lymphadenopathy - 23 percent",
"     </li>",
"     <li>",
"      Fever - 16 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Upper respiratory and gastrointestinal signs and symptoms are uncommon in Lyme disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/16\">",
"     16",
"    </a>",
"    ]. Their presence should suggest an alternate diagnosis, such as a viral infection.",
"   </p>",
"   <p>",
"    A study of patients enrolled in a Lyme vaccine trial addressed the question of the prevalence of early Lyme disease in patients lacking an EM lesion. Forty-two of 269 (16 percent) patients with definite or possible Lyme disease had systemic symptoms without EM; 18 of these had laboratory evidence of accompanying anaplasmosis, or babesiosis and possible Lyme disease, leaving 24 patients (9 percent) with laboratory-defined Lyme disease alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms in these 24 patients included arthralgias in 17, headache in 13, and neck stiffness in 10. While fever and chills were present in two-thirds of these patients, these symptoms were neither sustained nor prominent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/16\">",
"     16",
"    </a>",
"    ]. Lyme disease was confirmed in all 24 patients either by B. burgdorferi serologies (IgG variable major protein-like sequence-expressed sixth invariant region peptide enzyme-linked immunosorbent assay [VlsE C6 ELISA]",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sonicate Western blot) or a positive polymerase chain reaction for B. burgdorferi DNA in the blood. Although standard serologic tests for Lyme disease may be negative during the first several weeks of infection, one would expect to see seroconversion after that time if the patient has persistent infection. Moreover, a clinical picture of persistent or recurrent flu-like symptoms after antibiotic treatment in a seronegative patient is unlikely to be due to B. burgdorferi infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/48/28425?source=see_link\">",
"     \"Diagnosis of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Laboratory abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the prospective study of 79 patients with early Lyme disease and culture-confirmed EM cited above, the following laboratory abnormalities were identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Erythrocyte sedimentation rate more than twice the upper limit of normal (24 percent).",
"     </li>",
"     <li>",
"      Less frequent laboratory abnormalities included elevated serum creatine phosphokinase (12 percent), leukocytosis (5 percent), leukopenia (4 percent), anemia (3 percent), and thrombocytopenia (1.5 percent).",
"     </li>",
"     <li>",
"      Mildly elevated serum aspartate aminotransferase (AST)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      alanine aminotransferase (ALT) was observed in 37 percent of patients. However, this study was performed before the appreciable incidence of coinfection with Anaplasma",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      Babesia spp was recognized. Anaplasmosis may cause elevated aminotransferases, which could raise the incidence above that seen in patients who have Lyme disease alone. (see",
"      <a class=\"local\" href=\"#H26\">",
"       'Coinfection with other tick-borne pathogens'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/5/6234?source=see_link\">",
"       \"Human ehrlichiosis and anaplasmosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/25/39321?source=see_link\">",
"       \"Clinical manifestations, diagnosis, treatment, and prevention of babesiosis\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lyme serologies and other diagnostic tests are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/48/28425?source=see_link\">",
"     \"Diagnosis of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Spirochetemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood cultures for B. burgdorferi are not commercially available. However, in a cross-sectional study in which blood cultures for Borrelia burgdorferi were obtained in 213 untreated adults with EM, spirochetemia was present in 44 percent during the early phases (the first several weeks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/14\">",
"     14",
"    </a>",
"    ]. Although spirochetemic patients were significantly more likely to be symptomatic (89 versus 74 percent) and have multiple lesions (42 versus 15 percent) than those without spirochetemia, 8 of 35 asymptomatic patients (23 percent) with a single skin lesion had a positive blood culture. The risk for spirochetemia was present the day the patient noticed the lesion and continued for more than two weeks.",
"   </p>",
"   <p>",
"    In another study, blood cultures were positive in 5 of 26 untreated patients (19 percent) with early disseminated Lyme disease, with neurologic, cardiac, or musculoskeletal involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/17\">",
"     17",
"    </a>",
"    ]. Patients with a positive blood culture had a shorter duration of symptoms compared with those with a negative blood culture (mean 14 days versus 125 days, respectively). These findings suggest that spirochetemia occurs early in the course of infection. Positive blood cultures were associated with the presence of a concomitant EM lesion; positive blood cultures occurred in four of nine patients (44 percent) with EM versus 1 of 17 patients (6 percent) without EM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EARLY DISSEMINATED DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early disseminated Lyme disease with acute neurologic or cardiac involvement usually occurs weeks to several months after the tick bite and may be the first manifestation of Lyme disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Neurologic manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic features of early disseminated Lyme disease may include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/8,18\">",
"     8,18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lymphocytic meningitis",
"     </li>",
"     <li>",
"      Unilateral or bilateral cranial nerve palsies (especially of the facial nerve)",
"     </li>",
"     <li>",
"      Radiculopathy",
"     </li>",
"     <li>",
"      Peripheral neuropathy",
"     </li>",
"     <li>",
"      Mononeuropathy multiplex",
"     </li>",
"     <li>",
"      Cerebellar ataxia (rarely)",
"     </li>",
"     <li>",
"      Encephalomyelitis (rarely)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The classic triad of acute neurologic abnormalities is meningitis, cranial neuropathy, and motor or sensory radiculoneuropathy, although each of these findings may occur alone.",
"   </p>",
"   <p>",
"    Although the facial nerve is the most commonly affected cranial nerve, other nerves such as the abducens nerve may be involved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/19\">",
"     19",
"    </a>",
"    ]. Lyme disease is one of the few causes of bilateral cranial nerve palsies. Other causes include tuberculosis, sarcoidosis, and trauma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/23/36216?source=see_link\">",
"     \"Bell's palsy: Pathogenesis, clinical features, and diagnosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/2/28713?source=see_link\">",
"     \"Central nervous system tuberculosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Carditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac manifestations of Lyme disease include fluctuating degrees of atrioventricular heart block, sometimes with myopericarditis, which is usually mild when it occurs. Chronic cardiomyopathy with heart failure has been linked to Lyme disease in Europe, but not in the United States. Lyme carditis is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/51/40759?source=see_link\">",
"     \"Lyme carditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Ocular manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of ocular manifestations have been associated with Lyme disease, including conjunctivitis, keratitis, iridocyclitis, retinal vasculitis, choroiditis, optic neuropathy, and uveitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Except for conjunctivitis, which occurs in about 10 percent of patients early in the infection, all of the other manifestations are rare and described only in case reports in which validation of B. burgdorferi infection was sometimes limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cutaneous findings",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Borrelial lymphocytoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;In Europe, borrelial lymphocytoma is a rare cutaneous manifestation of Lyme disease that usually occurs during the early phase of infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/20,22-25\">",
"     20,22-25",
"    </a>",
"    ]. It presents as a single bluish-red swelling with a diameter of up to several centimeters, which usually occurs later and lasts longer than erythema migrans (EM), but resolves spontaneously. It is most commonly located on the earlobe in children and near the nipple in adults, and often occurs near a previous or concurrent EM lesion. Pathology reveals a dense lymphocytic infiltration of the cutis and subcutis.",
"   </p>",
"   <p>",
"    Reports from Europe have suggested a link between borrelial lymphocytoma caused by B. afzelii and primary cutaneous B cell lymphoma. However, this remains controversial and has been contradicted by studies from Asia and North America. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/9/19610?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas\", section on 'Disease associations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/6/15464?source=see_link&amp;anchor=H3#H3\">",
"     \"Primary cutaneous follicle center lymphoma\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     LATE DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late Lyme disease occurs months to a few years after the onset of infection and may not be preceded by a history of early localized or disseminated Lyme disease. In the United States, arthritis in one or a few joints is the most common feature of patients with late Lyme disease, but neurologic manifestations, such as a subtle encephalopathy or polyneuropathy can also occur. In Europe, patients may develop a chronic skin condition called acrodermatitis chronica atrophicans, but this manifestation has not been identified conclusively in the United States.",
"   </p>",
"   <p>",
"    These features are less common now since the majority of patients are diagnosed and treated during the early phase of Lyme disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lyme arthritis is characterized by intermittent or persistent arthritis in a few large joints, especially the knee [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/26\">",
"     26",
"    </a>",
"    ]. In the late 1970s, before the cause of Lyme disease and the role of antibiotics in its treatment were known, the natural history of articular manifestations of Lyme disease was described in a cohort of 55 patients followed prospectively from the onset of disease with erythema migrans (EM) through later manifestations of the illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Months after the onset of infection, about 60 percent of patients developed joint swelling and pain. A few small joints or periarticular sites (tendons or bursae) were also affected, primarily in early attacks. The number of patients who continued to have recurrent attacks decreased each year. However, in a small percentage of cases, involvement in large joints (usually one or both knees) became chronic and sometimes led to erosion of cartilage and bone. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/7/9336?source=see_link\">",
"     \"Musculoskeletal manifestations of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fibromyalgia can occur in the aftermath of Lyme disease, perhaps triggered by infection with B. burgdorferi, but fibromyalgia is not a feature of Lyme disease itself [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Neurologic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neurologic manifestations of late Lyme disease are different from those in early disseminated disease. In the United States, a mild neurologic syndrome, called Lyme encephalopathy, has been reported, manifested primarily by subtle cognitive disturbances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. In the United States and Europe, a chronic axonal polyneuropathy may develop, manifested primarily as spinal radicular pain or distal paresthesias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. In Europe, B. garinii may rarely cause chronic encephalomyelitis, characterized by spastic paraparesis, cranial neuropathy, or cognitive impairment with marked intrathecal antibody production to the spirochete [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The manifestations of early neurologic Lyme disease are discussed above. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Neurologic manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cutaneous manifestations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Acrodermatitis chronica atrophicans",
"    </span>",
"    &nbsp;&mdash;&nbsp;In Europe, acrodermatitis chronica atrophicans is the cutaneous manifestation of late Lyme disease that may appear years following primary infection (range 0.5 to 8 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/20,32-34\">",
"     20,32-34",
"    </a>",
"    ]. This condition is primarily due to B. afzelii and has not been described convincingly in the United States.",
"   </p>",
"   <p>",
"    Acrodermatitis chronica atrophicans is most common in women &gt;40 years of age, but it may occur in younger people. It is typically located on the extensor surfaces of the hands and feet.",
"   </p>",
"   <p>",
"    In its early stages, acrodermatitis chronica atrophicans has a slight bluish-red discoloration with associated swelling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/20\">",
"     20",
"    </a>",
"    ]. These lesions subsequently may slowly enlarge over months to years, and surrounding edema often resolves as atrophy develops. As a result, the underlying veins become prominent. Acrodermatitis chronica atrophicans usually begins as a unilateral lesion, but lesions may become bilateral over time.",
"   </p>",
"   <p>",
"    In Europe, fibrous induration or nodules (over bony prominences such as elbow or patella) may also develop in patients with late Lyme disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/20,33,34\">",
"     20,33,34",
"    </a>",
"    ]. Sclerotic lesions develop in other patients. These lesions can lead to peripheral nerve",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    joint damage. Histologic examination of such lesions reveal lymphocytic and plasma cell infiltrates in the dermis and sometimes the subcutis, with or without atrophy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;In Europe, morphea-like skin lesions have also been described as a rare manifestation of late Lyme disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/35\">",
"     35",
"    </a>",
"    ]. Histologic examination of these lesions typically reveals interstitial granulomatous dermatitis with histiocytic pseudorosettes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     POST-LYME DISEASE SYNDROME AND CHRONIC LYME DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several distinct syndromes have been described after recommended antibiotic therapy for Lyme disease. The term \"post-Lyme disease syndrome\" is often used to describe the nonspecific symptoms (such as headache, fatigue, and arthralgias) that may persist for months after treatment of Lyme disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. For the majority of patients, these symptoms improve gradually over six months to one year. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/54/27498?source=see_link&amp;anchor=H26#H26\">",
"     \"Treatment of Lyme disease\", section on 'Post-Lyme disease syndrome and chronic Lyme disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Infectious Diseases Society of America (IDSA) has proposed a definition of post-Lyme disease syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/8\">",
"     8",
"    </a>",
"    ]. Criteria for this syndrome include a prior history of Lyme disease treated with an accepted regimen and resolution or stabilization of the objective manifestations of Lyme disease. In addition, the onset of subjective symptoms (eg, fatigue, widespread musculoskeletal pain, complaints of cognitive difficulties) must have occurred within six months of the diagnosis of Lyme disease and persist (continuously or relapsing) for at least six months after completion of antimicrobial therapy. There are also several exclusion criteria (",
"    <a class=\"graphic graphic_table graphicRef74043 \" href=\"mobipreview.htm?3/53/3933\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The cause of persistent nonspecific symptoms after treatment for Lyme disease remains an area of uncertainty. Although there is evidence in animal models that B. burgdorferi can persist after antibiotic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/39,40\">",
"     39,40",
"    </a>",
"    ], a link to persistent symptoms in humans has not been established. The IDSA guidelines in 2006, the American Academy of Neurology practice parameter in 2007, and the Ad Hoc International Lyme Disease Group in 2007 concluded that currently available evidence does not support the hypothesis that persistent infection with B. burgdorferi is the cause of chronic subjective symptoms that may occur after recommended courses of antibiotic therapy for Lyme disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/8,41,42\">",
"     8,41,42",
"    </a>",
"    ]. The data supporting this conclusion are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/54/27498?source=see_link&amp;anchor=H26#H26\">",
"     \"Treatment of Lyme disease\", section on 'Post-Lyme disease syndrome and chronic Lyme disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The proportion of patients who develop post-Lyme disease syndrome is relatively small [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/42\">",
"     42",
"    </a>",
"    ]. Of the three major randomized trials of patients with post-Lyme disease syndrome, all had substantial difficulty in identifying subjects who met the entry criteria and therefore enrolled only a minority of those who were screened [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/36,38,43\">",
"     36,38,43",
"    </a>",
"    ]. The majority of the other patients typically have no evidence of having had Lyme disease, although many have been given a diagnosis of \"chronic Lyme disease.\"",
"   </p>",
"   <p>",
"    Chronic Lyme disease is a term that is used by some practitioners and patient advocacy groups. In its typical usage, it includes the post-Lyme disease syndrome described above, as well as illnesses and symptom complexes for which there is no convincing scientific evidence of any relationship to B. burgdorferi infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/42\">",
"     42",
"    </a>",
"    ]. Many of these patients have other recognizable syndromes or diagnoses. Among patients with nonspecific symptoms of fatigue and myalgias, these subjective symptoms are sometimes accompanied by tender points of fibromyalgia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/44\">",
"     44",
"    </a>",
"    ]. Since fibromyalgia is common in the general population, the association of Lyme disease and fibromyalgia may sometimes be by chance alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/8,45,46\">",
"     8,45,46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/7/9336?source=see_link&amp;anchor=H20#H20\">",
"     \"Musculoskeletal manifestations of Lyme disease\", section on 'Post-lyme disease syndrome (chronic lyme disease) and fibromyalgia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with late stage disease who develop arthritis, a small percentage have persistent arthritis after the completion of two to three months of oral and intravenous therapy. Antibiotic-treated patients with persistence of arthritis after clearance of B. burgdorferi DNA from the synovial fluid (as determined by polymerase chain reaction) do not respond to additional courses of antibiotics. The mechanism for persistence of arthritis is unclear; however, these patients may respond to antiinflammatory therapy. It has been hypothesized that infection of the joint may have triggered autoimmunity in the joints of these patients. In the absence of antiinflammatory therapy, \"antibiotic-refractory arthritis\" may persist for months to several years, but will eventually resolve spontaneously. Almost no patients have persistent symptoms extending past five years. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/7/9336?source=see_link\">",
"     \"Musculoskeletal manifestations of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     REINFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reinfection with B. burgdorferi is possible following the successful treatment of early Lyme disease. Reinfection typically presents as erythema migrans at a different location on the skin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 17 patients who received a diagnosis of erythema migrans between 1991 and 2011 and who had 22 paired episodes of erythema migrans, molecular typing of the B. burgdorferi gene encoding outer surface protein C (ospC) was performed using B. burgdorferi strains that were detected in cultures of skin or blood specimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/48\">",
"     48",
"    </a>",
"    ]. The ospC genotype was found to be different at each initial and second episode of erythema migrans, demonstrating that repeat episodes of erythema migrans in appropriately treated patients were due to reinfection rather than relapse.",
"    <br/>",
"   </p>",
"   <p>",
"    Reinfected patients may have a marked anamnestic immune response with rapid IgG isotype switching [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/46\">",
"     46",
"    </a>",
"    ]. However, in patients who are treated during the early stages of disease, this immune response is typically directed against antigens for which antibodies do not protect against reinfection or in which variations in proteins expressed by different strains of B. burgdorferi can thwart protection from these previously developed immune responses. In contrast, patients who have had late stage manifestations of Lyme disease often have an expanded antibody response to many additional antigens that protects against reinfection. Reinfection has not been reported in patients who previously had Lyme arthritis, a late disease manifestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because Borrelia species are spirochetes, there has been concern about the possibility of congenital Lyme disease given the serious congenital disease that can result from maternal syphilis, another spirochetal disease. Current evidence suggests that there is no definable congenital Lyme disease syndrome. If adequately treated, Lyme disease occurring during pregnancy does not predispose to congenital anomalies or fetal demise. A woman who has a history of Lyme disease diagnosed and treated before the pregnancy has no reason for concern.",
"   </p>",
"   <p>",
"    Diagnosis and treatment for Lyme disease during pregnancy is the same as in the nongravid patient, except that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    are not used. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/54/27498?source=see_link&amp;anchor=H25#H25\">",
"     \"Treatment of Lyme disease\", section on 'Pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Effect on fetuses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several early case reports and small studies suggested a link between maternal Lyme disease and congenital malformations or fetal demise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/50-54\">",
"     50-54",
"    </a>",
"    ]. However, more recent studies have not supported an association between Lyme disease in pregnancy and adverse fetal outcomes, congenital malformations, or cardiac malformations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/55-59\">",
"     55-59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective study, 2000 women residing in an endemic area had Lyme serology during their first prenatal visit and at delivery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/56\">",
"       56",
"      </a>",
"      ]. Neither a history of a tick bite nor serologic evidence of Lyme disease during pregnancy were associated with fetal death, decrease in infant birth weight, premature delivery, or congenital malformations.",
"     </li>",
"     <li>",
"      In a prospective study of pregnant women with erythema migrans treated during pregnancy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      , 51 of 58 (88 percent) delivered normal term babies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/57\">",
"       57",
"      </a>",
"      ]. Among the remaining seven pregnancies, there was one spontaneous abortion, five premature births, and one term baby with a urologic defect noted at seven months of age.",
"     </li>",
"     <li>",
"      A retrospective, case-control study of 1500 children, 796 with a congenital heart defect, showed no link between congenital heart disease and a history of maternal tick bite or maternal infection within three months of conception or during pregnancy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A survey of 162 pediatric neurologists from areas endemic for Lyme disease failed to identify a congenital neurologic Lyme disease syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these studies were fairly large, they were limited by the small number of women actually exposed to Lyme disease during pregnancy. Thus, while current data are reassuring, it is not clear that the power of the studies was sufficient to rule out a small increase in risk. What can be said, is that there is no accepted or well-described \"congenital Lyme disease syndrome,\" in marked contrast with the classic syndrome of congenital syphilis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant women from endemic areas or with a history of Lyme disease are often concerned about disease transmission. They should be reassured that:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is no evidence that Lyme disease can be transmitted by breast feeding.",
"     </li>",
"     <li>",
"      There is no evidence to suggest that Lyme disease can be transmitted by sexual or intimate contact.",
"     </li>",
"     <li>",
"      There is no evidence that Lyme disease can be transmitted by sharing silverware or drinking glasses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     COINFECTION WITH OTHER TICK-BORNE PATHOGENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Lyme disease in endemic areas may be coinfected with the other infections transmitted by Ixodes ticks: Anaplasma phagocytophilum, which causes human granulocytic anaplasmosis (HGA; previously called human granulocytic ehrlichiosis) and Babesia microti in the United States; and tick-borne encephalitis virus in Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/60-63\">",
"     60-63",
"    </a>",
"    ]. Borrelia miyamotoi, a Borrelia species related to the agents of relapsing fever, has been found in Ixodes ticks and in the same rodent reservoirs as for Lyme disease agents in North America, Europe, and Asia. Initial information about the clinical syndromes has been described in several patients with B. miyamotoi infection. Given that B. miyamotoi has been found in Ixodes ticks, it is likely that coinfection with B. miyamotoi and the Borrelia species that cause Lyme disease occurs, but information about serologic findings and the clinical pictures in coinfected patients is not yet available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/43/15033?source=see_link&amp;anchor=H343465099#H343465099\">",
"     \"Clinical features, diagnosis, and management of relapsing fever\", section on 'Borrelia miyamotoi infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reported rates of coinfection with babesiosis or HGA have ranged from 4 to 28 percent in endemic regions of the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/60,62\">",
"     60,62",
"    </a>",
"    ]. The differences in the reported rates of coinfection were probably due to the variation in prevalence of B. microti and A. phagocytophilum in the regions studied and in differences in the definitions of infection.",
"   </p>",
"   <p>",
"    The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 192 residents of areas with high rates of tick-borne infections (Block Island, RI; Nantucket, MA; southeastern Connecticut) who were diagnosed with a tick-borne disease, 75 (39 percent) were coinfected with more than one organism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/61\">",
"       61",
"      </a>",
"      ]. Lyme disease with babesiosis was responsible for 81 percent of coinfections, whereas 9 percent had Lyme disease with HGA, 5 percent had all three infections, and 4 percent had babesiosis with HGA.",
"     </li>",
"     <li>",
"      In other reports from southern New England, coinfection with B. microti occurred in 2 percent of patients with erythema migrans [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/62\">",
"       62",
"      </a>",
"      ], and 10 percent of those with serologic evidence of Lyme disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In studies from New England and Wisconsin, 2 to 12 percent of patients with erythema migrans were coinfected with A. phagocytophilum [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/62,64,65\">",
"       62,64,65",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Coinfected patients tend to have more prolonged and more severe symptoms (particularly higher fever, sweats, and rigors) than are usually seen with Lyme disease alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/60,63,65\">",
"     60,63,65",
"    </a>",
"    ]. However, this may be due in part to referral bias. No clinical symptoms clearly identify patients with coinfection. Standard blood counts may help since Lyme disease, by itself, rarely causes abnormalities. In contrast, anemia and thrombocytopenia often occur in babesiosis, whereas leukopenia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thrombocytopenia may occur in anaplasmosis. Both anaplasmosis and babesiosis are usually asymptomatic infections, but are more of a problem in the very young or very old, or, in the case of babesiosis, in those without a spleen. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Laboratory abnormalities'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/5/6234?source=see_link\">",
"     \"Human ehrlichiosis and anaplasmosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/25/39321?source=see_link\">",
"     \"Clinical manifestations, diagnosis, treatment, and prevention of babesiosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Investigation for coinfection with these pathogens is warranted in patients with suggestive clinical findings, moderate to severe Lyme disease, or persistent objective findings following recommended antimicrobial therapy for Lyme disease that does not have activity against possible coinfecting pathogens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35225/abstract/60,61,63\">",
"     60,61,63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/54/27498?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of Lyme disease\", section on 'Possible coinfection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/40/30338?source=see_link\">",
"       \"Patient information: Lyme disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/17/32022?source=see_link\">",
"       \"Patient information: Lyme disease symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/41/5778?source=see_link\">",
"       \"Patient information: Lyme disease treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/0/27649?source=see_link\">",
"       \"Patient information: Lyme disease prevention (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lyme disease is a tick-borne illness caused by three pathogenic species of the spirochete Borrelia burgdorferi sensu lato. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations of Lyme disease can generally be divided into three phases: early localized, early disseminated, and late disease (",
"      <a class=\"graphic graphic_table graphicRef72018 \" href=\"mobipreview.htm?39/7/40060\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical stages'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early localized disease includes erythema migrans (EM) and nonspecific findings that resemble a viral syndrome. EM occurs in approximately 80 percent of patients, usually within one month following the tick bite. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Early localized disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early disseminated Lyme disease with acute neurologic or cardiac involvement usually occurs weeks to several months after the tick bite and may be the first manifestation of Lyme disease. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Early disseminated disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Late Lyme disease occurs months to a few years after the onset of infection and may not be preceded by a history of early localized or disseminated Lyme disease. In the United States, arthritis in one or a few joints is the most common feature of patients with late Lyme disease, but neurologic manifestations, such as a subtle encephalopathy or polyneuropathy can also occur. In Europe, patients may develop a chronic skin condition called acrodermatitis chronica atrophicans, but this manifestation has not been identified conclusively in the United States. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Late disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonspecific symptoms (such as headache, fatigue, and arthralgias) may persist for months after treatment of Lyme disease. There is no evidence that these persistent subjective complaints represent ongoing active infection or that repeated or prolonged courses of antibiotics beyond what is recommended in the Infectious Diseases Society of America and American Academy of Neurology guidelines provide any benefit. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Post-Lyme disease syndrome and chronic Lyme disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Current evidence suggests that there is no definable congenital Lyme disease syndrome. Diagnosis and treatment for Lyme disease during pregnancy is the same as in the nongravid patient, except that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      are not used. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Coinfection of Borrelia burgdorferi with Babesia microti",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      Anaplasma phagocytophilum (the agent of human granulocytic anaplasmosis) occurs in a minority of patients since these organisms share the tick vector (Ixodes spp). (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Coinfection with other tick-borne pathogens'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/1\">",
"      Steere AC, Malawista SE, Snydman DR, et al. Lyme arthritis: an epidemic of oligoarticular arthritis in children and adults in three connecticut communities. Arthritis Rheum 1977; 20:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/2\">",
"      Steere AC, Malawista SE, Hardin JA, et al. Erythema chronicum migrans and Lyme arthritis. The enlarging clinical spectrum. Ann Intern Med 1977; 86:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/3\">",
"      Steere AC. Lyme disease. N Engl J Med 2001; 345:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/4\">",
"      Steere AC. Lyme disease. N Engl J Med 1989; 321:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/5\">",
"      Stanek G, Wormser GP, Gray J, Strle F. Lyme borreliosis. Lancet 2012; 379:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/6\">",
"      Strle F, Nadelman RB, Cimperman J, et al. Comparison of culture-confirmed erythema migrans caused by Borrelia burgdorferi sensu stricto in New York State and by Borrelia afzelii in Slovenia. Ann Intern Med 1999; 130:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/7\">",
"      Jones KL, Muellegger RR, Means TK, et al. Higher mRNA levels of chemokines and cytokines associated with macrophage activation in erythema migrans skin lesions in patients from the United States than in patients from Austria with Lyme borreliosis. Clin Infect Dis 2008; 46:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/8\">",
"      Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/9\">",
"      Steere AC, Sikand VK. The presenting manifestations of Lyme disease and the outcomes of treatment. N Engl J Med 2003; 348:2472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/10\">",
"      Nadelman RB, Nowakowski J, Forseter G, et al. The clinical spectrum of early Lyme borreliosis in patients with culture-confirmed erythema migrans. Am J Med 1996; 100:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/11\">",
"      Edlow JA. Erythema migrans. Med Clin North Am 2002; 86:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/12\">",
"      Hengge UR, Tannapfel A, Tyring SK, et al. Lyme borreliosis. Lancet Infect Dis 2003; 3:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/13\">",
"      Smith RP, Schoen RT, Rahn DW, et al. Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans. Ann Intern Med 2002; 136:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/14\">",
"      Wormser GP, McKenna D, Carlin J, et al. Brief communication: hematogenous dissemination in early Lyme disease. Ann Intern Med 2005; 142:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/15\">",
"      Steere AC, Bartenhagen NH, Craft JE, et al. The early clinical manifestations of Lyme disease. Ann Intern Med 1983; 99:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/16\">",
"      Steere AC, Dhar A, Hernandez J, et al. Systemic symptoms without erythema migrans as the presenting picture of early Lyme disease. Am J Med 2003; 114:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/17\">",
"      Nowakowski J, McKenna D, Nadelman RB, et al. Blood cultures for patients with extracutaneous manifestations of Lyme disease in the United States. Clin Infect Dis 2009; 49:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/18\">",
"      Halperin JJ. Nervous system Lyme disease. Infect Dis Clin North Am 2008; 22:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/19\">",
"      Sauer A, Hansmann Y, Jaulhac B, et al. Five cases of paralytic strabismus as a rare feature of lyme disease. Clin Infect Dis 2009; 48:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/20\">",
"      Stanek G, Strle F. Lyme borreliosis. Lancet 2003; 362:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/21\">",
"      Mikkil&auml; HO, Sepp&auml;l&auml; IJ, Viljanen MK, et al. The expanding clinical spectrum of ocular lyme borreliosis. Ophthalmology 2000; 107:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/22\">",
"      Strle F, Pleterski-Rigler D, Stanek G, et al. Solitary borrelial lymphocytoma: report of 36 cases. Infection 1992; 20:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/23\">",
"      Mullegger RR. Dermatological manifestations of Lyme borreliosis. Eur J Dermatol 2004; 14:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/24\">",
"      Colli C, Leinweber B, M&uuml;llegger R, et al. Borrelia burgdorferi-associated lymphocytoma cutis: clinicopathologic, immunophenotypic, and molecular study of 106 cases. J Cutan Pathol 2004; 31:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/25\">",
"      Picken RN, Strle F, Ruzic-Sabljic E, et al. Molecular subtyping of Borrelia burgdorferi sensu lato isolates from five patients with solitary lymphocytoma. J Invest Dermatol 1997; 108:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/26\">",
"      Steere AC, Schoen RT, Taylor E. The clinical evolution of Lyme arthritis. Ann Intern Med 1987; 107:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/27\">",
"      Dinerman H, Steere AC. Lyme disease associated with fibromyalgia. Ann Intern Med 1992; 117:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/28\">",
"      Logigian EL, Kaplan RF, Steere AC. Chronic neurologic manifestations of Lyme disease. N Engl J Med 1990; 323:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/29\">",
"      Halperin JJ, Luft BJ, Anand AK, et al. Lyme neuroborreliosis: central nervous system manifestations. Neurology 1989; 39:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/30\">",
"      Oschmann P, Dorndorf W, Hornig C, et al. Stages and syndromes of neuroborreliosis. J Neurol 1998; 245:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/31\">",
"      Logigian EL, Steere AC. Clinical and electrophysiologic findings in chronic neuropathy of Lyme disease. Neurology 1992; 42:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/32\">",
"      Balmelli T, Piffaretti JC. Association between different clinical manifestations of Lyme disease and different species of Borrelia burgdorferi sensu lato. Res Microbiol 1995; 146:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/33\">",
"      Asbrink E, Hovmark A, Olsson I. Clinical manifestations of acrodermatitis chronica atrophicans in 50 Swedish patients. Zentralbl Bakteriol Mikrobiol Hyg A 1986; 263:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/34\">",
"      Asbrink E, Hovmark A. Early and late cutaneous manifestations in Ixodes-borne borreliosis (erythema migrans borreliosis, Lyme borreliosis). Ann N Y Acad Sci 1988; 539:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/35\">",
"      Moreno C, Kutzner H, Palmedo G, et al. Interstitial granulomatous dermatitis with histiocytic pseudorosettes: a new histopathologic pattern in cutaneous borreliosis. Detection of Borrelia burgdorferi DNA sequences by a highly sensitive PCR-ELISA. J Am Acad Dermatol 2003; 48:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/36\">",
"      Klempner MS, Hu LT, Evans J, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001; 345:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/37\">",
"      Kaplan RF, Trevino RP, Johnson GM, et al. Cognitive function in post-treatment Lyme disease: do additional antibiotics help? Neurology 2003; 60:1916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/38\">",
"      Krupp LB, Hyman LG, Grimson R, et al. Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology 2003; 60:1923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/39\">",
"      Bockenstedt LK, Mao J, Hodzic E, et al. Detection of attenuated, noninfectious spirochetes in Borrelia burgdorferi-infected mice after antibiotic treatment. J Infect Dis 2002; 186:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/40\">",
"      Hodzic E, Feng S, Holden K, et al. Persistence of Borrelia burgdorferi following antibiotic treatment in mice. Antimicrob Agents Chemother 2008; 52:1728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/41\">",
"      Halperin JJ, Shapiro ED, Logigian E, et al. Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2007; 69:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/42\">",
"      Feder HM Jr, Johnson BJ, O'Connell S, et al. A critical appraisal of \"chronic Lyme disease\". N Engl J Med 2007; 357:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/43\">",
"      Fallon BA, Keilp JG, Corbera KM, et al. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology 2008; 70:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/44\">",
"      Lightfoot RW Jr, Luft BJ, Rahn DW, et al. Empiric parenteral antibiotic treatment of patients with fibromyalgia and fatigue and a positive serologic result for Lyme disease. A cost-effectiveness analysis. Ann Intern Med 1993; 119:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/45\">",
"      Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995; 38:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/46\">",
"      Nadelman RB, Wormser GP. Reinfection in patients with Lyme disease. Clin Infect Dis 2007; 45:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/47\">",
"      Krause PJ, Foley DT, Burke GS, et al. Reinfection and relapse in early Lyme disease. Am J Trop Med Hyg 2006; 75:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/48\">",
"      Nadelman RB, Hanincov&aacute; K, Mukherjee P, et al. Differentiation of reinfection from relapse in recurrent Lyme disease. N Engl J Med 2012; 367:1883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/49\">",
"      Steere AC. Reinfection versus relapse in Lyme disease. N Engl J Med 2012; 367:1950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/50\">",
"      Schlesinger PA, Duray PH, Burke BA, et al. Maternal-fetal transmission of the Lyme disease spirochete, Borrelia burgdorferi. Ann Intern Med 1985; 103:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/51\">",
"      MacDonald AB, Benach JL, Burgdorfer W. Stillbirth following maternal Lyme disease. N Y State J Med 1987; 87:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/52\">",
"      Weber K, Bratzke HJ, Neubert U, et al. Borrelia burgdorferi in a newborn despite oral penicillin for Lyme borreliosis during pregnancy. Pediatr Infect Dis J 1988; 7:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/53\">",
"      Markowitz LE, Steere AC, Benach JL, et al. Lyme disease during pregnancy. JAMA 1986; 255:3394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/54\">",
"      Williams CL, Strobino B, Weinstein A, et al. Maternal Lyme disease and congenital malformations: a cord blood serosurvey in endemic and control areas. Paediatr Perinat Epidemiol 1995; 9:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/55\">",
"      Silver HM. Lyme disease during pregnancy. Infect Dis Clin North Am 1997; 11:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/56\">",
"      Strobino BA, Williams CL, Abid S, et al. Lyme disease and pregnancy outcome: a prospective study of two thousand prenatal patients. Am J Obstet Gynecol 1993; 169:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/57\">",
"      Maraspin V, Cimperman J, Lotric-Furlan S, et al. Treatment of erythema migrans in pregnancy. Clin Infect Dis 1996; 22:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/58\">",
"      Strobino B, Abid S, Gewitz M. Maternal Lyme disease and congenital heart disease: A case-control study in an endemic area. Am J Obstet Gynecol 1999; 180:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/59\">",
"      Gerber MA, Zalneraitis EL. Childhood neurologic disorders and Lyme disease during pregnancy. Pediatr Neurol 1994; 11:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/60\">",
"      Swanson SJ, Neitzel D, Reed KD, Belongia EA. Coinfections acquired from ixodes ticks. Clin Microbiol Rev 2006; 19:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/61\">",
"      Krause PJ, McKay K, Thompson CA, et al. Disease-specific diagnosis of coinfecting tickborne zoonoses: babesiosis, human granulocytic ehrlichiosis, and Lyme disease. Clin Infect Dis 2002; 34:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/62\">",
"      Steere AC, McHugh G, Suarez C, et al. Prospective study of coinfection in patients with erythema migrans. Clin Infect Dis 2003; 36:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/63\">",
"      Krause PJ, Telford SR 3rd, Spielman A, et al. Concurrent Lyme disease and babesiosis. Evidence for increased severity and duration of illness. JAMA 1996; 275:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/64\">",
"      Belongia EA, Reed KD, Mitchell PD, et al. Clinical and epidemiological features of early Lyme disease and human granulocytic ehrlichiosis in Wisconsin. Clin Infect Dis 1999; 29:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35225/abstract/65\">",
"      Horowitz HW, Aguero-Rosenfeld ME, Holmgren D, et al. Lyme disease and human granulocytic anaplasmosis coinfection: impact of case definition on coinfection rates and illness severity. Clin Infect Dis 2013; 56:93.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7913 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-197.136.42.3-97C5FA2E12-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_25_35225=[""].join("\n");
var outline_f34_25_35225=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL STAGES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      UNITED STATES VERSUS EUROPE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EARLY LOCALIZED DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Erythema migrans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Laboratory abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Spirochetemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EARLY DISSEMINATED DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Neurologic manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Carditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Ocular manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cutaneous findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Borrelial lymphocytoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      LATE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Neurologic features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cutaneous manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Acrodermatitis chronica atrophicans",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      POST-LYME DISEASE SYNDROME AND CHRONIC LYME DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      REINFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Effect on fetuses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Transmission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      COINFECTION WITH OTHER TICK-BORNE PATHOGENS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7913\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7913|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/10/10400\" title=\"picture 1\">",
"      Erythema migrans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/35/575\" title=\"picture 2\">",
"      Erythema migrans uniform",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/20/35140\" title=\"picture 3\">",
"      EM vesicular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/47/27382\" title=\"picture 4A\">",
"      Erythema migrans Biopsy I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/59/12214\" title=\"picture 4B\">",
"      Erythema migrans Biopsy II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/16/26883\" title=\"picture 5\">",
"      Erythema migrans multiple",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/18/6436\" title=\"picture 6\">",
"      Erythema migrans - early disseminated Lyme",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/19/33086\" title=\"picture 7\">",
"      STARI rash",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7913|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/7/40060\" title=\"table 1\">",
"      Signs of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/53/3933\" title=\"table 2\">",
"      Post Lyme disease syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/23/36216?source=related_link\">",
"      Bell's palsy: Pathogenesis, clinical features, and diagnosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/2/28713?source=related_link\">",
"      Central nervous system tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/43/15033?source=related_link\">",
"      Clinical features, diagnosis, and management of relapsing fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/51/14135?source=related_link\">",
"      Clinical manifestations and diagnosis of Rocky Mountain spotted fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/25/39321?source=related_link\">",
"      Clinical manifestations, diagnosis, treatment, and prevention of babesiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/9/19610?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/48/28425?source=related_link\">",
"      Diagnosis of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/5/6234?source=related_link\">",
"      Human ehrlichiosis and anaplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/35/28216?source=related_link\">",
"      Insect bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/51/40759?source=related_link\">",
"      Lyme carditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/3/7225?source=related_link\">",
"      Lyme disease: Clinical manifestations in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/7/9336?source=related_link\">",
"      Musculoskeletal manifestations of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/40/30338?source=related_link\">",
"      Patient information: Lyme disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/0/27649?source=related_link\">",
"      Patient information: Lyme disease prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/17/32022?source=related_link\">",
"      Patient information: Lyme disease symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/41/5778?source=related_link\">",
"      Patient information: Lyme disease treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/6/15464?source=related_link\">",
"      Primary cutaneous follicle center lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26533?source=related_link\">",
"      Southern tick-associated rash illness (STARI)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/54/27498?source=related_link\">",
"      Treatment of Lyme disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_25_35226="Early noncardiac complications of coronary artery bypass graft surgery";
var content_f34_25_35226=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Early noncardiac complications of coronary artery bypass graft surgery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/25/35226/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/25/35226/contributors\">",
"     Sary Aranki, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/25/35226/contributors\">",
"     Julian M Aroesty, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/25/35226/contributors\">",
"     Rakesh M Suri, MD, DPhil",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/25/35226/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/25/35226/contributors\">",
"     Gabriel S Aldea, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/25/35226/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/25/35226/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/25/35226/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/25/35226/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of coronary heart disease (CHD) has evolved significantly over the past several years due in part to improvement in both surgical and percutaneous revascularization techniques. The majority of patients with chronic stable angina are still treated with medical therapy; however, revascularization with either coronary artery bypass graft surgery (CABG) or percutaneous coronary intervention (PCI) should be considered in several subgroups. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/51/9018?source=see_link\">",
"     \"Medical therapy versus revascularization in the management of stable angina pectoris\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major complications associated with coronary artery bypass graft surgery are death, myocardial infarction, stroke, wound infection, prolonged requirement for mechanical ventilation, acute kidney injury, and bleeding requiring transfusion or reoperation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The short-term, particularly perioperative, noncardiac complications that can occur following conventional CABG (using cardiopulmonary bypass) will be reviewed here. Cardiac complications and perioperative mortality after CABG are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/28/39368?source=see_link\">",
"     \"Early cardiac complications of coronary artery bypass graft surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/38/22120?source=see_link\">",
"     \"Operative mortality after coronary artery bypass graft surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVENTION OF COMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many complications related to traditional techniques of cardiac surgery are primarily the result of cardiopulmonary bypass (CPB). An important factor is aortic instrumentation and manipulation, including cannulation, decannulation, and partial or complete clamping and unclamping, which can result in dislodgement of atherosclerotic debris and embolization from diseased aortas. Technical errors in bypass graft construction that can lead to graft occlusion, primarily in saphenous vein grafts, also may be important [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10809?source=see_link\">",
"     \"Embolism from aortic plaque: Thromboembolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other factors that contribute to complications include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Global cardiac arrest",
"     </li>",
"     <li>",
"      Hypothermia",
"     </li>",
"     <li>",
"      Nonpulsatile bypass and artificial perfusion",
"     </li>",
"     <li>",
"      An intense \"inflammatory\" response to perfusion with artificial (nonendothelialized) surfaces",
"     </li>",
"     <li>",
"      The reintroduction of fat and particulate debris as well as procoagulant and proinflammatory factors from the pericardial surgical field into the systemic circulation via the use of cardiotomy (field) suction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The sternotomy and skin incision",
"     </li>",
"     <li>",
"      Conduit harvest",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Minimal extracorporeal CPB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Off-pump CABG (OP CABG) procedures are considered to be less invasive than full CPB. Data from randomized trials and observational studies are conflicting as to whether or not there is an improvement in clinical outcomes such as mortality and stroke with OP CABG. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37031?source=see_link&amp;anchor=H4#H4\">",
"     \"Off-pump and minimally invasive direct coronary artery bypass graft surgery: Outcomes\", section on 'Off-pump CABG'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CPB systems designed to decrease the rates of the complications discussed above (particularly stroke) have also been evaluated. One such device, the mini-extracorporeal circulation (MECC), is a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    bonded CPB circuit that requires a relatively small prime for the centrifugal pump, and does not include either an open venous reservoir (which minimizes blood-air contact), or direct reinfusion of cardiotomy suction from the pericardial space. This design has the potential to limit the systemic inflammatory response seen with traditional CPB.",
"   </p>",
"   <p>",
"    In an initial prospective trial, 300 CABG patients were randomly assigned to MECC or OP CABG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/9\">",
"     9",
"    </a>",
"    ]. There were no differences between the two groups in operative mortality and morbidity, transfusion rates, hospital stay, or serum levels of creatine kinase and inflammatory markers including interleukin-6. In a study of 40 consecutive patients undergoing CABG who were randomly assigned to either MECC or standard CPB, the former was shown to be a safe alternative. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Improvements in surgical technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Improvements in surgical technique have led to a steady reduction in morbidity after CABG, despite the fact that patients currently undergoing CABG have higher risk profiles. This was illustrated in a report that compared 5051 patients undergoing CABG from 1986 to 1988 with 2793 patients undergoing CABG from 1993 to 1994 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/1\">",
"     1",
"    </a>",
"    ]. Although the patients in the latter period were at higher cardiovascular risk, the risk-adjusted morbidity rate decreased from 14.5 to 8.8 percent with no change in risk-adjusted hospital mortality (2.8 versus 2.9 percent). A later report that evaluated over 37,000 patients undergoing CABG for multivessel disease in New York state between 1997 and 2000 found an in-hospital mortality of only 1.8 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following are some of the improvements in technique that have reduced postoperative complications:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complications related to aortic manipulation can be limited by routine, careful evaluation of the ascending aorta using intraoperative transesophageal and epiaortic echocardiography to identify mobile and intramural atheromatous disease, and to help define safe areas for cannulation. Aortic manipulation also can be decreased using a \"single-clamp\" technique. By avoiding the application of an additional partial occlusion clamp to construct proximal anastomoses, neurologic complications can be reduced, although not eliminated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Advances have been made in the composition of cardioplegia fluid (eg, blood versus crystalloid) as well as substrate enhancement with aspartate and glutamate and superoxide radical scavengers. These advances, used in conjunction with integration of different routes of cardioplegia administration (antegrade, retrograde and down the newly constructed grafts) to effect homogeneous delivery to all parts of the heart beyond coronary artery blockages, have resulted in more optimal myocardial protection. As a result, the heart can be safely arrested for as long as two hours with minimal cardiac dysfunction, allowing precise repair of complex problems [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Normothermic or near normothermic systemic perfusion is now routinely used. Avoiding systemic hypothermia decreases coagulation abnormalities and organ dysfunction.",
"     </li>",
"     <li>",
"      Many of the complications of CABG are related to the biologic response of the body to artificial perfusion and gas exchange through the nonendothelialized cardiopulmonary bypass (CPB) circuit. Within seconds of CPB, formed and unformed blood elements come into contact with the large surface area of the CPB circuit. Despite anticoagulation with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , this interaction results in extensive activation of platelets, neutrophils, complement, cytokines and the fibrinolytic system, producing a complex and intense \"inflammatory\" response. Although these responses are usually short-lived and leave no residual deficits, they can lead to long-lasting cardiac, pulmonary, renal, and neurologic dysfunction in a subset of patients.",
"     </li>",
"     <li>",
"      Advances in perfusion technology and techniques and research in biomaterial sciences have resulted in the application of more biocompatible CPB circuits, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      -bonded circuits. The use of these circuits has reduced the need for homologous transfusion and decreased neutrophil and complement activation, resulting in reductions in thromboembolic complications (including neurologic dysfunction), myocardial and pulmonary dysfunction, and cost [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/14-19\">",
"       14-19",
"      </a>",
"      ]. Elimination of cardiotomy suction is an important adjunct by minimizing inflammation, thrombin and platelet activation, and the increase in markers of neuronal injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Active leukocyte depletion of transfused blood during CPB and of autologous saved blood prior to reinfusion can reduce perioperative morbidity, particularly when more than three blood transfusions are required [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/20\">",
"       20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/5/24665?source=see_link\">",
"       \"Leukoreduction to prevent complications of blood transfusion\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional pharmacologic interventions and perfusion surface modifications to further attenuate platelet, neutrophil, and complement activation and cytokine release are being actively investigated. As an example, direct C5 inhibition with a recombinant, humanized antibody during CPB blunts complement activation, proinflammatory byproducts, and leukocyte activation, and may result in decreased myocardial injury, blood loss, and new cognitive deficits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/38/10854?source=see_link\">",
"     \"Regulators and receptors of the complement system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Technical errors in bypass graft construction can lead to graft occlusion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]. Such patients should undergo emergency surgical",
"      <span class=\"nowrap\">",
"       re-exploration/revision",
"      </span>",
"      or coronary angiography. Hybrid operating room catheterization laboratories have been used to perform \"completion angiography\" of bypass grafts, and fluorescent angiographic techniques can be performed without angiography.",
"      <br/>",
"      <br/>",
"      In a report of a novel technique, intraoperative angiography using fluorescent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/44/32450?source=see_link\">",
"       indocyanine green",
"      </a>",
"      dye resulted in graft revision (all but one saphenous vein grafts) for technical problems in 4.2 percent of patients that would otherwise have gone unrecognized [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/5\">",
"       5",
"      </a>",
"      ]. The test took 2.2 minutes to perform. Further studies are required.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2004 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines on bypass surgery issued general recommendations for preventive measures to minimize the risk of some of these complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prophylactic antimicrobials to prevent surgical site infection",
"     </li>",
"     <li>",
"      Strict glycemic control (using an insulin infusion) during the perioperative period, which also may reduce sternal wound infection",
"     </li>",
"     <li>",
"      An antifibrinolytic agent is used in most CABG procedures to minimize bleeding.",
"     </li>",
"     <li>",
"      Beta blockers,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , and statins are indicated in many patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The evidence supporting the efficacy of these therapies is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/26/40360?source=see_link\">",
"     \"Medical therapy to prevent complications after coronary artery bypass graft surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28602?source=see_link&amp;anchor=H13#H13\">",
"     \"Atrial fibrillation and flutter after cardiac surgery\", section on 'Prevention of AF and complications'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H18\">",
"     'Sternal wound infection and mediastinitis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H12\">",
"     'Antifibrinolytic agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition to these medical therapies, carotid duplex ultrasound may be performed to identify severe carotid stenosis in patients with an audible bruit, severe peripheral artery disease, or a previous stroke or transient ischemic attack. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/7/2168?source=see_link\">",
"     \"Prevention of neurologic complications of cardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Minimally invasive CABG",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding discussion applied to conventional CABG using CPB. Off-pump (OP) CABG has been evaluated as a minimally invasive approach. Clinical trials comparing the two approaches have suggested that OP CABG may reduce morbidity but there is concern about long-term graft patency. These issues as well as patient selection for OP CABG are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37031?source=see_link&amp;anchor=H4#H4\">",
"     \"Off-pump and minimally invasive direct coronary artery bypass graft surgery: Outcomes\", section on 'Off-pump CABG'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 30 percent of patients require a blood transfusion after CABG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/23\">",
"     23",
"    </a>",
"    ]. In addition, bleeding requiring reoperation is associated with large increases in transfusion requirements and intensive care unit and hospital stays. Rates of reoperation have ranged from 4 to 6 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/24\">",
"     24",
"    </a>",
"    ], although one study found that, during 1995 to 1997, there was a reduction in the rate of reoperation to 2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/25\">",
"     25",
"    </a>",
"    ]. Although reoperation is usually performed in the operating room, reoperation in the intensive care unit is feasible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to preoperatively identify patients at high risk for requiring blood, one study of 1007 patients undergoing a first CABG developed a prediction rule based upon data from two-thirds of the sample and prospectively applied it to the remaining one-third [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/23\">",
"     23",
"    </a>",
"    ]. Independent factors predicting the need of transfusion were lower preoperative hemoglobin, lower weight, older age, and female gender.",
"   </p>",
"   <p>",
"    Additional risk factors for perioperative transfusion include preoperative use of antiplatelet or antithrombotic drugs, reoperation, acquired or congenital",
"    <span class=\"nowrap\">",
"     clotting/coagulation",
"    </span>",
"    abnormalities, complex procedures, and emergency operations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Antiplatelet agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiplatelet agents have a variable effect on bleeding risk.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      &mdash; Evidence suggests that late (less than 5 days prior to surgery) discontinuation of aspirin did not decrease adverse cardiovascular events but did increase the risk of perioperative blood transfusion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/28\">",
"       28",
"      </a>",
"      ]. It is generally recommended that aspirin be started in the early postoperative period to reduce both mortality and morbidity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/29\">",
"       29",
"      </a>",
"      ]. However, with increasing experience, some surgeons recommend continuation of aspirin throughout the preoperative period. The possible risk of aspirin therapy in patients undergoing CABG, including recommendations for the timing of aspirin therapy, is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/26/40360?source=see_link&amp;anchor=H2#H2\">",
"       \"Medical therapy to prevent complications after coronary artery bypass graft surgery\", section on 'Aspirin'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/45/40666?source=see_link&amp;anchor=H26#H26\">",
"       \"Perioperative medication management\", section on 'Aspirin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       Clopidogrel",
"      </a>",
"      &mdash; Clopidogrel therapy within five days of CABG is associated with an increased bleeding risk. Two reports comparing the bleeding risk with or without recent clopidogrel use in (mostly) stable patients undergoing CABG are available [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]. The larger of the two is a retrospective observational study of 1572 consecutive patients who underwent nonemergent off-pump CABG (OP CABG); 281 (18 percent) had either received a 300 mg loading dose before PCI or had been on oral clopidogrel within seven days of surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/31\">",
"       31",
"      </a>",
"      ]. Patients with, compared to those without, recent clopidogrel use had a significantly increased need for packed red blood transfusion and of reoperation for bleeding (6.4 versus 1.4 percent, odds ratio 5.1 on multivariable analysis). There was no difference in operative mortality between the two groups (1.4 percent). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37031?source=see_link\">",
"       \"Off-pump and minimally invasive direct coronary artery bypass graft surgery: Outcomes\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      However, among those patients who receive clopidogrel within five to seven days of surgery, the risk of bleeding is more likely related to the residual antiplatelet effect of the drug than the number of days since the last dose. In a prospective study of 100 patients who received clopidogrel within five days of off pump CABG, blood loss (and transfusion requirement) was significantly greater in patients in the third tercile of the percentage of platelet inhibitory response to clopidogrel (greatest residual clopidogrel effect) as assessed by thromboelastography, compared to those in the first and second tertiles (914 vs 623 and 683 ml, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/32\">",
"       32",
"      </a>",
"      ]. In multivariate analysis, discontinuation date did not significantly predict either the degree of blood loss or transfusion requirement. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/59/23482?source=see_link&amp;anchor=H25#H25\">",
"       \"Platelet function testing\", section on 'Thromboelastography'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      referred for CABG have generally been placed on it either for prevention of cardiovascular events after an acute coronary syndrome or for the prevention of stent thrombosis after stent placement. In these settings, discontinuation of clopidogrel prior to the recommended duration places the patient at increased risk. Thus, the timing of discontinuation of clopidogrel requires consideration of both the benefit (less bleeding) and risk (increased rate of ischemic events) of its discontinuation. The 2004",
"      <span class=\"nowrap\">",
"       ACC/AHA",
"      </span>",
"      guidelines on CABG and the 2008 American College of Chest Physicians (ACCP) guidelines on the primary and secondary prevention of coronary heart artery recommend five (preferably seven) days off clopidogrel before CABG [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=see_link&amp;anchor=H21914160#H21914160\">",
"       \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Bleeding risk'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10634?source=see_link\">",
"       \"Antiplatelet therapy after coronary artery stenting\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The decision whether to perform CABG within five days of clopidogrel use in an individual patient requires an analysis of the risks and benefits. Local institutional and surgeon preferences need to be taken into account.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"       Prasugrel",
"      </a>",
"      ��� Bleeding at the time of CABG is also a concern for prasugrel. In the Triton trial comparing",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      with prasugrel in patients with acute coronary syndrome, major bleeding occurred at a significantly higher rate among those receiving prasugrel (13.4 versus 3.2 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitors &mdash; The effect of glycoprotein",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      antagonists on bleeding risk is less clear. One report evaluated surgical outcomes in 85 patients in the EPILOG and EPISTENT trials who required emergency CABG after",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"       abciximab",
"      </a>",
"      therapy for percutaneous coronary intervention [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/36\">",
"       36",
"      </a>",
"      ]. These patients, compared to those not treated with abciximab, had no significant increase in major blood loss or red cell transfusion and no reduction in the use of optimal IMA grafts. However, abciximab-treated patients were more likely to require surgical reexploration for bleeding (12 versus 3 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H534837610\">",
"    <span class=\"h4\">",
"     Stopping and restarting P2Y12 receptor blocker",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision as to when to discontinue platelet P2Y12 receptor blocker therapy prior to CABG must balance the perioperative risks of bleeding (discussed above) while on and acute ischemic events while off dual antiplatelet therapy.",
"   </p>",
"   <p>",
"    The possible role of bridging therapy with cangrelor, an intravenous P2Y12 receptor blocker with a half life of three to six minutes, was evaluated in the BRIDGE trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/37\">",
"     37",
"    </a>",
"    ]. In BRIDGE, 210 patients awaiting CABG with an acute coronary syndrome or treated with a coronary stent and receiving either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    were randomly assigned to either cangrelor or placebo after discontinuation of the thienopyridine. Study drug was continued for at least 48 hours and was then discontinued one to six hours before CABG. As expected, cangrelor, compared to placebo, was associated with a significantly lower level of platelet reactivity (platelet reactivity units &lt;240, 98.8 versus 19.0 percent). However, it was not associated with any significant difference in CABG surgery-related bleeding (11.8 versus 10. 4 percent, respectively). As BRIDGE did not test the hypothesis that bridging therapy would improve outcomes compared to either early discontinuation or continuation of P2Y12 receptor blocker therapy, we do not recommend such an approach (cangrelor is not commercially available).",
"   </p>",
"   <p>",
"    There is not good evidence upon which a recommendation can be made as to when to restart P2Y12 receptor blocker therapy after CABG. Our reviewers generally wait until the risk of major bleeding has significantly fallen, perhaps 12 to 24 hours after uncomplicated surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of intraoperative ACT-guided",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    dosing is appropriate in patients undergoing CABG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/36\">",
"     36",
"    </a>",
"    ]. Although some have suggested benefit from the selective use of platelet transfusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/38\">",
"     38",
"    </a>",
"    ], a prospective report of over 5000 patients undergoing CABG noted increases in mortality and ischemic complications with platelet transfusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/29\">",
"     29",
"    </a>",
"    ]. The latter observation and the benefit of postoperative",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy are consistent with a central role for platelet activation in the ischemic response to reperfusion injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Antifibrinolytic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability of the antifibrinolytic agents &mdash;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/38/30311?source=see_link\">",
"     aminocaproic acid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/52/6982?source=see_link\">",
"     aprotinin",
"    </a>",
"    &mdash; to prevent bleeding following both on- and off-pump CABG is well established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/39-42\">",
"     39-42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relative efficacy and safety of these three antifibrinolytic drugs were addressed in a meta-analysis of 128 mostly small randomized controlled trials (published prior to August 2006) that compared the efficacy and safety of the three agents to placebo and to each other in patients undergoing CABG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/39\">",
"     39",
"    </a>",
"    ]. Compared to placebo, all agents were effective at reducing blood loss by 226 to 348 mL and at lowering the proportion of patients transfused with packed red blood cells. In head-to-head comparisons, high dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/52/6982?source=see_link\">",
"     aprotinin",
"    </a>",
"    was more effective at reducing blood loss than either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/38/30311?source=see_link\">",
"     aminocaproic acid",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The meta-analysis found no statistically important worsening of the outcomes of mortality, stroke, myocardial infarction, or dialysis-dependent renal failure. However, high dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/52/6982?source=see_link\">",
"     aprotinin",
"    </a>",
"    significantly increased the risk of temporary kidney injury, defined as an increase in serum creatinine (relative risk 1.47, 95% CI 1.12-1.94). An increased likelihood of acute kidney injury (AKI) with aprotinin was also seen in observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/43-45\">",
"     43-45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized trial and two large observational studies published after the meta-analysis provided evidence for an increase in both short and long term mortality in patients who received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/52/6982?source=see_link\">",
"     aprotinin",
"    </a>",
"    compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/38/30311?source=see_link\">",
"     aminocaproic acid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    , or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/46-48\">",
"     46-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The BART trial (Blood conservation using Antifibrinolytics in a Randomized Trial) was designed to further evaluate the safety of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/52/6982?source=see_link\">",
"     aprotinin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/48\">",
"     48",
"    </a>",
"    ]. After enrollment of 2331 of 3000 patients scheduled to be randomly assigned to either aprotinin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/38/30311?source=see_link\">",
"     aminocaproic acid",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    , the trial was terminated early because of a significantly higher death rate in patients receiving aprotinin.",
"   </p>",
"   <p>",
"    Similar findings were noted in a retrospective analysis of data from over 33,000",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/52/6982?source=see_link\">",
"     aprotinin",
"    </a>",
"    recipients and over 44,000",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/38/30311?source=see_link\">",
"     aminocaproic acid",
"    </a>",
"    recipients in which the unadjusted risk of death within the first seven days after CABG was 4.5 and 2.5 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/46\">",
"     46",
"    </a>",
"    ]. After adjustment for 41 patient and hospital characteristics, the relative risk of death was significantly increased in the aprotinin group (relative risk 1.64, 95% CI 1.50-1.78). Another retrospective analysis found that the mortality risk with aprotinin remained significantly increased at one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The inability of the meta-analysis cited above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/39\">",
"     39",
"    </a>",
"    ] to detect the mortality risk seen in BART illustrates the pitfalls of aggregating data from multiple small randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/49\">",
"     49",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/52/6982?source=see_link\">",
"     Aprotinin",
"    </a>",
"    is not available for routine use in the United States. The European Medicines Agency recommended lifting suspension of marketing of aprotinin in early 2012 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2008 meta-analysis of 11 trials (436 patients) that evaluated the effects of prophylactic glucocorticoids found that their use resulted in a small but significant decrease in the rate of postoperative bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/51\">",
"     51",
"    </a>",
"    ]. However, we do not recommend prophylactic glucocorticoid use for this purpose, as the results of the individual trials in the meta-analysis were heterogeneous and only four studies reported transfusion rates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Blood transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia is an independent risk factor for morbidity and mortality after CABG, and as a consequence, red blood cell (RBC) transfusion is common. Rates of transfusion between 40 and 90 percent have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/52\">",
"     52",
"    </a>",
"    ]. In a 2010 report of over 82,000 patients (from United States hospitals that performed at least 100 on-pump CABG operations) who underwent primary isolated CABG surgery with cardiopulmonary bypass during 2008, the rate of perioperative RBC transfusion was 56.1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/53\">",
"     53",
"    </a>",
"    ]. However, the hospital rates varied between 8 and 93 percent.",
"   </p>",
"   <p>",
"    There are reasons to avoid transfusion. Patients who undergo transfusion have worse outcomes compared to those who do not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/52\">",
"     52",
"    </a>",
"    ]. It is not known for certain whether these worse outcomes are related directly to adverse consequences of transfusion or whether transfusion is a surrogate for other unaccounted-for risks. In addition, RBC transfusion is associated with increased financial cost, the consumption of limited resources, and risks such as infection or transfusion reaction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11769?source=see_link\">",
"     \"Immunologic blood transfusion reactions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/14/10471?source=see_link\">",
"     \"Transfusion transmitted bacterial infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/46/10986?source=see_link\">",
"     \"The approach to the patient who refuses blood transfusion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/56/37766?source=see_link\">",
"     \"Transfusion-associated immune and non immune-mediated hemolysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/39/28282?source=see_link\">",
"     \"Transfusion-related acute lung injury (TRALI)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/28/31175?source=see_link\">",
"     \"Transfusion transmitted HIV infection and AIDS\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, the optimal transfusion strategy, including the level below which RBC transfusion clearly improves outcomes, is uncertain.",
"   </p>",
"   <p>",
"    The issue of whether a restrictive perioperative RBC transfusion strategy is as safe as liberal strategy was evaluated in the TRACS noninferiority trial. In TRACS, 502 patients who underwent cardiac surgery with cardiopulmonary bypass were randomly assigned to a liberal (hematocrit &ge;30 percent) or a restrictive (hematocrit &ge;24 percent) strategy of blood transfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/52\">",
"     52",
"    </a>",
"    ]. Patients were transfused, at any time from the start of surgery until discharge, if the hematocrit was less than 30 percent in the liberal group or less than 24 percent in the restrictive groups. The primary composite endpoint included all-cause mortality and severe morbidity [cardiogenic shock, acute respiratory distress syndrome, or acute renal injury requiring dialysis or hemofiltration] at 30 days. The following findings were noted in the liberal and restrictive groups respectively:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemoglobin concentrations were 10.5 and 9.1",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"     </li>",
"     <li>",
"      The rates of transfusion were 78 and 47 percent.",
"     </li>",
"     <li>",
"      There was no statistically significant difference in the rate of the primary endpoint (10 versus 11 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As pointed out by the authors, the absence of blood leukodepletion in this study may limit its generalizability. (See",
"    <a class=\"local\" href=\"#H1916969895\">",
"     'Leukoreduced blood'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The 2007 Society of Thoracic Surgeons and Society of Cardiovascular Anesthesiologists clinical practice guidelines on perioperative blood transfusion and blood conservation in cardiac surgery concluded that the transfusion of red blood cells for a hemoglobin level less than 6",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    is reasonable and can be life-saving, transfusion for a hemoglobin less than 7",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    is reasonable although high-level evidence is not available to support this approach, and that transfusion was not unreasonable in selected patients with hemoglobin values of 7 to 10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/27\">",
"     27",
"    </a>",
"    ]. These recommendations are not very different from those for the general use of RBC transfusion. This issue as well as the method of red blood cell transfusion and the options for what to do for patients unwilling or unable to be transfused are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/46/10986?source=see_link\">",
"     \"The approach to the patient who refuses blood transfusion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/52/5961?source=see_link\">",
"     \"Indications for red cell transfusion in the adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Until there is further evidence that could help to shape recommendations for RBC transfusion in CABG patients, some authors suggest that RBC transfusion be withheld for a hemoglobin of &gt;8",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    in most cases. However, the threshold for transfusion (below a hemoglobin of 8",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    should be individualized, and take into account clinical factors such as the age of the patient or whether the person is entering the diuretic phase after surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1916969895\">",
"    <span class=\"h3\">",
"     Leukoreduced blood",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients who required blood transfusion, leukoreduced blood may improve outcomes. The need for multiple blood transfusions and the infusion of allogeneic leukocytes is associated with an increase in complications including antigen-antibody formation, transmission of viruses, febrile reactions, and possibly impaired wound healing and postoperative infections.",
"   </p>",
"   <p>",
"    The potential efficacy of leukoreduced blood was illustrated in a trial that randomly assigned 944 patients undergoing cardiac surgery to receive packed cells or blood that was leukocyte depleted by filtration if transfusion was required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/20\">",
"     20",
"    </a>",
"    ]. Those receiving leukocyte depleted blood had a reduced incidence of infection compared to patients receiving packed cells, and a significant reduction in mortality at 60 days. This was particularly evident when more than three units of blood were required. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/5/24665?source=see_link\">",
"     \"Leukoreduction to prevent complications of blood transfusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Duration of red cell storage and outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Longer red blood cell storage times are associated with structural and functional changes that may worsen outcomes in the recipient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/54\">",
"     54",
"    </a>",
"    ]. In a retrospective study of over 6000 patients who underwent open heart surgery and were transfused, those who received blood stored for more than 14 days had significantly worse outcomes (intubation beyond 72 hours, renal failure, sepsis or septicemia, and in-hospital and one-year mortality) compared to those with shorter storage times [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, other studies have not demonstrated an independent effect of red cell storage time on outcomes after coronary artery bypass graft surgery and any potential benefits of using blood stored for two weeks or less must be weighed against the difficulty of maintaining the blood supply if only fresher units are used for transfusion. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/37/21081?source=see_link&amp;anchor=H12#H12\">",
"     \"Use of red blood cells for transfusion\", section on 'Clinical relevance of storage time'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     NEUROLOGIC COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic complications are an important source of morbidity and mortality after CABG. The major neurologic problems are stroke, neuropsychiatric abnormalities such as cognitive dysfunction, and peripheral neuropathy. The risk increases with patient age (",
"    <a class=\"graphic graphic_figure graphicRef68686 \" href=\"mobipreview.htm?14/21/14685\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanisms, risk factors, and possible therapies and preventive measures for neurologic complications after CABG and issues related to CABG in patients with known carotid artery disease are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/47/3834?source=see_link\">",
"     \"Neurologic complications of cardiac surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/7/2168?source=see_link\">",
"     \"Prevention of neurologic complications of cardiac surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/29/6617?source=see_link\">",
"     \"Coronary artery bypass grafting in patients with cerebrovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     INFECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Sternal wound infection and mediastinitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to postoperative sternal wound infection with mediastinitis are discussed in detail separately. The following discussion will be limited to issues related to CABG. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/48/1800?source=see_link\">",
"     \"Postoperative mediastinitis after cardiac surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14858?source=see_link\">",
"     \"Surgical management of sternal wound complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mediastinitis after CABG has been reported in 0.9 to 1.3 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/57-60\">",
"     57-60",
"    </a>",
"    ]. It is usually detected within the first two weeks (median about seven days), but the onset is delayed for more than one month in occasional patients. Virtually all patients have fever, tachycardia, chest pain or sternal instability, signs of sternal wound infection, and purulent discharge from the mediastinal area. Fever and systemic symptoms appear first in most patients. Streptococcus and Staphylococcus are the most frequent organisms.",
"   </p>",
"   <p>",
"    A number of risk factors have been identified for the development of mediastinitis after CABG, although the same risk factors were not noted in all studies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14858?source=see_link&amp;anchor=H1319298#H1319298\">",
"     \"Surgical management of sternal wound complications\", section on 'Risk factors for sternal wound complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obesity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/58,60,61\">",
"       58,60,61",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Diabetes mellitus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/57,58,62,63\">",
"       57,58,62,63",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Bilateral IMA grafts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/57,58\">",
"       57,58",
"      </a>",
"      ], a relationship that has not been confirmed in some studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/60,64\">",
"       60,64",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Prolonged duration of surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/58,60\">",
"       58,60",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Prior cardiac surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/60\">",
"       60",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Use of staples for skin closure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/62\">",
"       62",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Underlying obstructive airways disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/61\">",
"       61",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Dual antiplatelet therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      (compared with aspirin alone) within 5 days of surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among patients with diabetes, strict perioperative glycemic control appears to reduce the risk of sternal wound infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/15/30970?source=see_link&amp;anchor=H9#H9\">",
"     \"Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease\", section on 'Nonfatal adverse events'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mediastinitis after CABG is associated with increases in both short-term and long-term mortality. This was illustrated in a report of 6459 consecutive patients, 83 (1.3 percent) of whom developed mediastinitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/60\">",
"     60",
"    </a>",
"    ]. The patients with mediastinitis compared to those without this complication had increased mortality at 90 days (11.8 versus 5.5 percent); the interval mortality remained high between one and two years after surgery (8.1 versus 2.3 percent).",
"   </p>",
"   <p>",
"    The prevention and management of mediastinitis is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/48/1800?source=see_link\">",
"     \"Postoperative mediastinitis after cardiac surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14858?source=see_link\">",
"     \"Surgical management of sternal wound complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Leg wound complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported incidence of leg wound complications after saphenous vein graft (SVG) harvesting has varied widely, ranging from around 1 to 24 percent in older reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/66-71\">",
"     66-71",
"    </a>",
"    ], and 18 percent in a 2004 report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/72\">",
"     72",
"    </a>",
"    ]. The most common manifestations are usually minor and do not require surgical intervention. These include dermatitis, cellulitis, greater saphenous neuropathy, chronic nonhealing ulcers, and lymphocele.",
"   </p>",
"   <p>",
"    Major complications are rare. In a retrospective review of 3525 CABG procedures, lower extremity wound complications occurred in 4 percent of patients; however, only 0.65 percent required additional surgical intervention, including wound debridement, skin grafting, vascular procedure, amputation, or fasciotomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/68\">",
"     68",
"    </a>",
"    ]. Significant predictors of major wound complications were female gender, peripheral artery disease, and postoperative intraaortic balloon pump.",
"   </p>",
"   <p>",
"    For patients in whom a conventional (open) harvesting has been used, the wound may be closed with either staples or sutures. A 2010 Cochrane systemic review (updated in 2012) of three trials including over 300 patients found no significant difference in the rates of leg wound infection (10.8 versus 8.0 percent, respectively) or dehiscence (9.3 versus 8.8 percent) between these two techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/73\">",
"     73",
"    </a>",
"    ]. However, all included studies were felt to be of sub-optimal methodological quality and at risk of bias.",
"   </p>",
"   <p>",
"    Endoscopic SVG harvesting was developed in the mid-1990s as a way to improve postoperative discomfort and to potentially reduce wound infection. It is estimated that nearly 70 percent of all procedures performed in 2008 in the United States used the endoscopic technique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/74\">",
"     74",
"    </a>",
"    ]. Most studies have shown that the rate of leg wound complications is significantly reduced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/69-71,74\">",
"     69-71,74",
"    </a>",
"    ]. In a 2012 report of over 235,000 patients in the United States Society for Thoracic Surgery database (2003 to 2008), the use of endoscopic vein-graft harvesting was associated with a reduction in the rate of wound complications compared to open procedures (3.0 versus 3.6 percent; risk&ndash;adjusted hazard ratio 0.83, 95% CI 0.77-0.89) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/74\">",
"     74",
"    </a>",
"    ]. Our experts believe the current incidence of serious leg wound complications is significantly less than the rate quoted in this study at their institutions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Recurrent cellulitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cellulitis, which may be recurrent, is an unusual syndrome that presents months to years after saphenous venectomy and may be confused with deep vein thrombosis. Although it is uncommon to identify an infecting pathogen, antimicrobial therapy directed against beta-hemolytic streptococci and Staphylococcus aureus usually results in the prompt resolution of systemic complaints and slower resolution of the lower extremity changes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/44/24262?source=see_link\">",
"     \"Recurrent cellulitis after saphenous venectomy for coronary artery bypass graft surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Bloodstream infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bloodstream infection (BSI), defined as &ge;1 positive blood culture for a known pathogen with additional criteria for positive cultures caused by potential skin contaminants, occurred in 3 percent of patients within 90 days of undergoing CABG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/75\">",
"     75",
"    </a>",
"    ]. Individuals with BSI had a significantly increased risk of death (HR 4.2) and the risk was highest among those with BSI due to gram-negative bacteria or Staphylococcus aureus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     ACUTE KIDNEY INJURY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute kidney injury (AKI, previously called acute renal failure) is a potential complication of CABG that can arise from a variety of causes including intraoperative hypotension, postoperative cardiac complications that impair renal perfusion, hemolysis, atheroemboli, and exposure to contrast media [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. Reduced renal function due to transient hypoperfusion or contrast nephropathy usually resolves within a few days but some patients develop more severe and persistent kidney injury with a requirement for dialysis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4170?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis\", section on 'Pathology and pathogenesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10457?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;One problem with the available data on the incidence of AKI after CABG is the variable definitions used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/78\">",
"     78",
"    </a>",
"    ]. The incidence is higher with smaller compared to larger reductions in estimated glomerular filtration rate (eg, 25 percent increase in serum creatinine compared to a 100 percent increase or the requirement for dialysis). In two studies of 843 and 649 patients undergoing cardiac surgery (mostly CABG), the incidence of AKI (defined as a rise in the serum creatinine of only 25 percent) was 17 and 24 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. Using this definition, a patient whose serum creatinine rose from 1.0 to 1.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (88 to 115",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    would be considered to have AKI.",
"   </p>",
"   <p>",
"    Other contemporary studies that used a more restrictive definition noted a much lower rate of AKI. Two large series (one involving over 51,000 CABG procedures and a 2006 report from the Society of Thoracic Surgery [STS]) defined AKI as either an increase of serum creatinine to &gt;2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (177",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    with a minimum doubling of the preoperative value, or a new requirement for dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. The overall rate of AKI ranged from 3.6 to 5 percent and did not vary over time. In the STS report, a higher rate of 7.5 and 12.9 percent was noted when CABG was combined with aortic or mitral valve replacement, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A lower proportion of patients (0.9 to 1.7 percent in different large series) develops AKI severe enough to require dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/83-86\">",
"     83-86",
"    </a>",
"    ] and a reduced estimated creatinine clearance is a major risk factor for the development of AKI requiring dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/83-85\">",
"     83-85",
"    </a>",
"    ]. The magnitude of this effect was illustrated in a study using the Society of Thoracic Surgeons National Adult Cardiac Database of over 480,000 patients who underwent isolated CABG from 2000 to 2003 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/83\">",
"     83",
"    </a>",
"    ]. The rate of requirement of new dialysis was 0.2 percent in the 23 percent of patients with normal baseline renal function (estimated creatinine clearance &ge;90",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    compared to 0.5, 1.8, and 10.9 percent in patients with an estimated creatinine clearance of 60 to 89, 30 to 59, and less than 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 (adjusted odds ratio 1.7, 4.7, and 20.4, respectively). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link&amp;anchor=H20658806#H20658806\">",
"     \"Assessment of kidney function\", section on 'Assessment of GFR'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A study of over 2400 patients undergoing CABG after catheterization study found that the risk of AKI was highest in those undergoing preoperative coronary angiography within one day (24 percent) of CABG surgery compared to those having the test performed at least 5 days prior to surgery (15.8 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to baseline kidney dysfunction, preoperative risk factors for AKI include New York Heart Association functional class IV (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ), valve surgery, peripheral artery disease, emergent or urgent surgery, obesity, and the need for preoperative intraaortic balloon pump [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/84,85,88,89\">",
"     84,85,88,89",
"    </a>",
"    ]. Perioperative factors such as anemia, red blood cell transfusions, prolonged cardiopulmonary bypass, and surgical reexploration are also associated with the development of AKI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multivariable risk models to predict cardiac surgery associated AKI using either presurgical [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/85,90\">",
"     85,90",
"    </a>",
"    ] or presurgical and intrasurgical clinical information have been developed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/91\">",
"     91",
"    </a>",
"    ]. We do not routinely use these risk prediction models.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a strong relationship between the development of perioperative acute kidney injury and both short and long term mortality after CABG. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/2/37930?source=see_link\">",
"     \"Long-term outcome after coronary artery bypass graft surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/2/37930?source=see_link&amp;anchor=H24#H24\">",
"     \"Long-term outcome after coronary artery bypass graft surgery\", section on 'Chronic kidney disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The methods that may prevent AKI, including the possible benefit with an off-pump approach in patients undergoing CABG, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/10/42154?source=see_link&amp;anchor=H7#H7\">",
"     \"Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     OTHER COMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Venous thromboembolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deep venous thrombosis (DVT) and pulmonary embolism (PE) may be difficult to recognize after CABG and are therefore likely to be underdiagnosed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/92\">",
"     92",
"    </a>",
"    ]. In a series of 330 patients who underwent venous ultrasonography four to six days after CABG, DVT was present in 20 percent, and two patients had symptomatic PE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/93\">",
"     93",
"    </a>",
"    ]. Most such patients remain asymptomatic. This was illustrated in a review of hospital discharge records for 66,180 patients undergoing CABG in which only 736 (1.1 percent) were diagnosed with symptomatic DVT or PE within three months of surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/94\">",
"     94",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35305?source=see_link\">",
"     \"Approach to the diagnosis and therapy of lower extremity deep vein thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=see_link\">",
"     \"Diagnosis of acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prophylactic measures, such as graduated compression stockings and anticoagulation, can reduce the incidence of venous thromboembolism after surgical procedures. Recommendations for thromboembolism prophylaxis are presented in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Pulmonary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary complications after cardiac surgery are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/51/13113?source=see_link\">",
"     \"Strategies to reduce postoperative pulmonary complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/40/38537?source=see_link&amp;anchor=H21#H21\">",
"     \"Postoperative complications among patients undergoing cardiac surgery\", section on 'Pulmonary dysfunction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pleural effusions are common postoperatively occurring in up to 90 percent of patients who have undergone CABG. The effusions are usually small, left sided, and do not require treatment. Early effusions (within 30 days of CABG) tend to be bloody, while late effusions are yellow exudates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/95\">",
"     95",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/21/16728?source=see_link\">",
"     \"Pleural effusions following cardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Aortic dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ascending aortic dissection is a rare complication of CABG, occurring with both conventional on-pump CABG and, perhaps more often, with minimally invasive OP CABG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/96-99\">",
"     96-99",
"    </a>",
"    ]. In a review from a single institution, ascending aortic dissection occurred in 1 of 2723 patients (0.04 percent) treated with conventional CABG and 3 of 308 undergoing OP CABG (1 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/98\">",
"     98",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/16/44296?source=see_link\">",
"     \"Minimally invasive coronary artery bypass graft surgery: Definitions and technical issues\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dissection can occur intraoperatively or weeks to months after surgery. The site of aortic dissection is usually related to the partial occlusion clamp site, proximal vein graft anastomosis, and the site of cardioplegia delivery. Patients at increased risk are older adults and those with long standing hypertension, severe atherosclerotic involvement of the ascending aorta, or ectasia of aorta. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/19/25914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of aortic dissection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Protamine reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protamine is administered intravenously to reverse the effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , but may be associated with severe systemic reactions, including hypotension that may require inotropic support, an increase in pulmonary artery pressure, noncardiogenic pulmonary edema, and bronchospasm. In a series of 2069 patients, 2.6 percent had an adverse reaction within 10 minutes of protamine administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/100\">",
"     100",
"    </a>",
"    ]. Independent risk factors for an adverse event were NPH insulin use, fish allergy, and a history of nonprotamine medication allergy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not a complication of surgery itself, the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is associated with thrombocytopenia in 1 to 4 percent of patients. One study tested for heparin-dependent antiplatelet antibodies in 111 patients prior to and after CABG; approximately 20 percent had detectable antibodies prior to surgery as a result of previous heparin exposure, generally for treatment of unstable angina or failed angioplasty [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/101\">",
"     101",
"    </a>",
"    ]. Such patients may be at increased risk for heparin-induced thrombocytopenia and it may be prudent to avoid the use of postoperative heparin.",
"   </p>",
"   <p>",
"    In patients with a history of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -induced thrombocytopenia who are antibody negative, heparin use should be restricted to the operative period only; postoperative anticoagulation, if necessary, should be achieved with alternative anticoagulants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/102,103\">",
"     102,103",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40890?source=see_link&amp;anchor=H44#H44\">",
"     \"Heparin-induced thrombocytopenia\", section on 'Use of heparin after an episode of HIT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A major complication of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -induced thrombocytopenia is venous and arterial thrombosis, which may increase the risk of SVG, but not internal mammary artery occlusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/104\">",
"     104",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40890?source=see_link&amp;anchor=H12#H12\">",
"     \"Heparin-induced thrombocytopenia\", section on 'Thrombosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Gastrointestinal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single center reports have found serious gastrointestinal (GI) complications in 0.3 to 3 percent of patients undergoing cardiac surgery, primarily CABG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/105,106\">",
"     105,106",
"    </a>",
"    ]. Mortality in these patients has been as high as 33 percent.",
"   </p>",
"   <p>",
"    The largest reported experience comes from the United States Agency for Healthcare Research and Quality, which assessed the incidence and impact of GI complications after 2.7 million CABG operations performed from 1998 to 2002 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/107\">",
"     107",
"    </a>",
"    ]. The most frequent reported complications were abscess, ileus, gastrointestinal ulcer",
"    <span class=\"nowrap\">",
"     (perforation/bleeding),",
"    </span>",
"    and bleeding diverticulosis or diverticulitis in the colon. The following observations were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of GI complications was 4.1 percent. The largest increase in relative risk was seen in patients over age 65 and those on hemodialysis. In contrast, use of an internal mammary graft was associated with lower risk.",
"     </li>",
"     <li>",
"      The inpatient mortality was significantly increased in those with GI complications compared to those without (12.0 versus 2.5 percent). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/38/22120?source=see_link\">",
"       \"Operative mortality after coronary artery bypass graft surgery\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     EARLY READMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Readmission rates varied between 8.3 to 21.1 percent following CABG in an analysis of the New York State Registry. The most common reasons were post-operative infection (16.9 percent), heart failure (12.8 percent), and \"other complications\" (9.8 percent). The authors found that the following variables were independently associated with increased readmission risk: older age, female sex, African-American race, higher body mass index, comorbidities, renal failure, unplanned cardiac reoperation, United States Medicare or Medicaid status, discharge to a skilled nursing facility, saphenous vein grafts, and longer length of stay. Readmission was not found to correlate with mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/108\">",
"     108",
"    </a>",
"    ]. Other studies report that rates of readmission range between 13 to 16 percent at four to six weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/25/35226/abstract/109-112\">",
"     109-112",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/62/31717?source=see_link\">",
"       \"Patient information: Coronary artery bypass graft surgery (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/16/23813?source=see_link\">",
"       \"Patient information: Recovery after coronary artery bypass graft surgery (CABG) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H99231126\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many of the noncardiac complications related coronary artery bypass graft (CABG) surgery are the result of either cardiopulmonary bypass or aortic instrumentation and manipulation. Preventative strategies are available. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prevention of complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bleeding, neurologic complications, infection, and acute kidney injury are four of the most important adverse outcomes after CABG.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Approximately 30 percent of patients require a blood transfusion after CABG. Risk factors include lower preoperative hemoglobin, lower weight, older age, and female gender. Additional risk factors for perioperative transfusion include preoperative use of antiplatelet or antithrombotic drugs, reoperation, acquired or congenital",
"      <span class=\"nowrap\">",
"       clotting/coagulation",
"      </span>",
"      abnormalities, complex procedures, and emergency operations. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major neurologic problems are stroke, neuropsychiatric abnormalities such as cognitive dysfunction, and peripheral neuropathy. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Neurologic complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sternal wound infection and mediastinitis after CABG occur in approximately one percent of patients. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Sternal wound infection and mediastinitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute kidney injury is a potential complication of CABG that can arise from a variety of causes including intraoperative hypotension, postoperative cardiac complications that impair renal perfusion, hemolysis, atheroemboli, and exposure to contrast media. Approximately 1 to 2 percent of patients require dialysis. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Acute kidney injury'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/1\">",
"      Estafanous FG, Loop FD, Higgins TL, et al. Increased risk and decreased morbidity of coronary artery bypass grafting between 1986 and 1994. Ann Thorac Surg 1998; 65:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/2\">",
"      Hammermeister KE, Burchfiel C, Johnson R, Grover FL. Identification of patients at greatest risk for developing major complications at cardiac surgery. Circulation 1990; 82:IV380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/3\">",
"      Magovern JA, Sakert T, Magovern GJ, et al. A model that predicts morbidity and mortality after coronary artery bypass graft surgery. J Am Coll Cardiol 1996; 28:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/4\">",
"      Fortescue EB, Kahn K, Bates DW. Development and validation of a clinical prediction rule for major adverse outcomes in coronary bypass grafting. Am J Cardiol 2001; 88:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/5\">",
"      Desai ND, Miwa S, Kodama D, et al. Improving the quality of coronary bypass surgery with intraoperative angiography: validation of a new technique. J Am Coll Cardiol 2005; 46:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/6\">",
"      Alderman EL, Levy JH, Rich JB, et al. Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. J Thorac Cardiovasc Surg 1998; 116:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/7\">",
"      Reents W, Babin-Ebell J, Misoph MR, et al. Influence of different autotransfusion devices on the quality of salvaged blood. Ann Thorac Surg 1999; 68:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/8\">",
"      Aldea GS, Soltow LO, Chandler WL, et al. Limitation of thrombin generation, platelet activation, and inflammation by elimination of cardiotomy suction in patients undergoing coronary artery bypass grafting treated with heparin-bonded circuits. J Thorac Cardiovasc Surg 2002; 123:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/9\">",
"      Mazzei V, Nasso G, Salamone G, et al. Prospective randomized comparison of coronary bypass grafting with minimal extracorporeal circulation system (MECC) versus off-pump coronary surgery. Circulation 2007; 116:1761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/10\">",
"      Liu Y, Tao L, Wang X, et al. Beneficial effects of using a minimal extracorporeal circulation system during coronary artery bypass grafting. Perfusion 2012; 27:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/11\">",
"      Hannan EL, Racz MJ, Walford G, et al. Long-term outcomes of coronary-artery bypass grafting versus stent implantation. N Engl J Med 2005; 352:2174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/12\">",
"      Aranki SF, Rizzo RJ, Adams DH, et al. Single-clamp technique: an important adjunct to myocardial and cerebral protection in coronary operations. Ann Thorac Surg 1994; 58:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/13\">",
"      Buckberg GD. Update on current techniques of myocardial protection. Ann Thorac Surg 1995; 60:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/14\">",
"      Gu YJ, van Oeveren W, Akkerman C, et al. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1993; 55:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/15\">",
"      Ovrum E, Mollnes TE, Fosse E, et al. High and low heparin dose with heparin-coated cardiopulmonary bypass: activation of complement and granulocytes. Ann Thorac Surg 1995; 60:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/16\">",
"      von Segesser LK, Weiss BM, Pasic M, et al. Risk and benefit of low systemic heparinization during open heart operations. Ann Thorac Surg 1994; 58:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/17\">",
"      Ovrum E, Holen EA, Tangen G, et al. Completely heparinized cardiopulmonary bypass and reduced systemic heparin: clinical and hemostatic effects. Ann Thorac Surg 1995; 60:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/18\">",
"      Aldea GS, Doursounian M, O'Gara P, et al. Heparin-bonded circuits with a reduced anticoagulation protocol in primary CABG: a prospective, randomized study. Ann Thorac Surg 1996; 62:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/19\">",
"      Aldea GS, O'Gara P, Shapira OM, et al. Effect of anticoagulation protocol on outcome in patients undergoing CABG with heparin-bonded cardiopulmonary bypass circuits. Ann Thorac Surg 1998; 65:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/20\">",
"      van de Watering LM, Hermans J, Houbiers JG, et al. Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: a randomized clinical trial. Circulation 1998; 97:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/21\">",
"      Fitch JC, Rollins S, Matis L, et al. Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation 1999; 100:2499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/22\">",
"      Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 2004; 110:e340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/23\">",
"      Karkouti K, Cohen MM, McCluskey SA, Sher GD. A multivariable model for predicting the need for blood transfusion in patients undergoing first-time elective coronary bypass graft surgery. Transfusion 2001; 41:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/24\">",
"      Sellman M, Intonti MA, Ivert T. Reoperations for bleeding after coronary artery bypass procedures during 25 years. Eur J Cardiothorac Surg 1997; 11:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/25\">",
"      Munoz JJ, Birkmeyer NJ, Dacey LJ, et al. Trends in rates of reexploration for hemorrhage after coronary artery bypass surgery. Northern New England Cardiovascular Disease Study Group. Ann Thorac Surg 1999; 68:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/26\">",
"      Fiser SM, Tribble CG, Kern JA, et al. Cardiac reoperation in the intensive care unit. Ann Thorac Surg 2001; 71:1888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/27\">",
"      Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris VA, Ferraris SP, et al. Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg 2007; 83:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/28\">",
"      Jacob M, Smedira N, Blackstone E, et al. Effect of timing of chronic preoperative aspirin discontinuation on morbidity and mortality in coronary artery bypass surgery. Circulation 2011; 123:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/29\">",
"      Mangano DT, Multicenter Study of Perioperative Ischemia Research Group. Aspirin and mortality from coronary bypass surgery. N Engl J Med 2002; 347:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/30\">",
"      Hongo RH, Ley J, Dick SE, Yee RR. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol 2002; 40:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/31\">",
"      Kapetanakis EI, Medlam DA, Petro KR, et al. Effect of clopidogrel premedication in off-pump cardiac surgery: are we forfeiting the benefits of reduced hemorrhagic sequelae? Circulation 2006; 113:1667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/32\">",
"      Kwak YL, Kim JC, Choi YS, et al. Clopidogrel responsiveness regardless of the discontinuation date predicts increased blood loss and transfusion requirement after off-pump coronary artery bypass graft surgery. J Am Coll Cardiol 2010; 56:1994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/33\">",
"      Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). J Am Coll Cardiol 2004; 44:e213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/34\">",
"      Becker RC, Meade TW, Berger PB, et al. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:776S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/35\">",
"      Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/36\">",
"      Lincoff AM, LeNarz LA, Despotis GJ, et al. Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials. Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibition in STENTing. Ann Thorac Surg 2000; 70:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/37\">",
"      Angiolillo DJ, Firstenberg MS, Price MJ, et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 2012; 307:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/38\">",
"      Juergens CP, Yeung AC, Oesterle SN. Routine platelet transfusion in patients undergoing emergency coronary bypass surgery after receiving abciximab. Am J Cardiol 1997; 80:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/39\">",
"      Brown JR, Birkmeyer NJ, O'Connor GT. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 2007; 115:2801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/40\">",
"      Sedrakyan A, Treasure T, Elefteriades JA. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg 2004; 128:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/41\">",
"      Ray MJ, O'Brien MF. Comparison of epsilon aminocaproic acid and low-dose aprotinin in cardiopulmonary bypass: efficiency, safety and cost. Ann Thorac Surg 2001; 71:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/42\">",
"      Adler Ma SC, Brindle W, Burton G, et al. Tranexamic acid is associated with less blood transfusion in off-pump coronary artery bypass graft surgery: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth 2011; 25:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/43\">",
"      Mangano DT, Tudor IC, Dietzel C, et al. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/44\">",
"      Mouton R, Finch D, Davies I, et al. Effect of aprotinin on renal dysfunction in patients undergoing on-pump and off-pump cardiac surgery: a retrospective observational study. Lancet 2008; 371:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/45\">",
"      Karkouti K, Beattie WS, Dattilo KM, et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion 2006; 46:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/46\">",
"      Schneeweiss S, Seeger JD, Landon J, Walker AM. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med 2008; 358:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/47\">",
"      Shaw AD, Stafford-Smith M, White WD, et al. The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med 2008; 358:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/48\">",
"      Fergusson DA, H&eacute;bert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008; 358:2319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/49\">",
"      Ray WA. Learning from aprotinin--mandatory trials of comparative efficacy and safety needed. N Engl J Med 2008; 358:840.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.ema.europa.eu/ema/pages/news_and_events/news/2012/02/news_detail_001447.jsp.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/51\">",
"      Whitlock RP, Chan S, Devereaux PJ, et al. Clinical benefit of steroid use in patients undergoing cardiopulmonary bypass: a meta-analysis of randomized trials. Eur Heart J 2008; 29:2592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/52\">",
"      Hajjar LA, Vincent JL, Galas FR, et al. Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial. JAMA 2010; 304:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/53\">",
"      Bennett-Guerrero E, Zhao Y, O'Brien SM, et al. Variation in use of blood transfusion in coronary artery bypass graft surgery. JAMA 2010; 304:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/54\">",
"      Andreasen JJ, Dethlefsen C, Modrau IS, et al. Storage time of allogeneic red blood cells is associated with risk of severe postoperative infection after coronary artery bypass grafting. Eur J Cardiothorac Surg 2011; 39:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/55\">",
"      Koch CG, Li L, Sessler DI, et al. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med 2008; 358:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/56\">",
"      Roach GW, Kanchuger M, Mangano CM, et al. Adverse cerebral outcomes after coronary bypass surgery. Multicenter Study of Perioperative Ischemia Research Group and the Ischemia Research and Education Foundation Investigators. N Engl J Med 1996; 335:1857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/57\">",
"      Borger MA, Rao V, Weisel RD, et al. Deep sternal wound infection: risk factors and outcomes. Ann Thorac Surg 1998; 65:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/58\">",
"      Loop FD, Lytle BW, Cosgrove DM, et al. J. Maxwell Chamberlain memorial paper. Sternal wound complications after isolated coronary artery bypass grafting: early and late mortality, morbidity, and cost of care. Ann Thorac Surg 1990; 49:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/59\">",
"      Braxton JH, Marrin CA, McGrath PD, et al. Mediastinitis and long-term survival after coronary artery bypass graft surgery. Ann Thorac Surg 2000; 70:2004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/60\">",
"      Milano CA, Kesler K, Archibald N, et al. Mediastinitis after coronary artery bypass graft surgery. Risk factors and long-term survival. Circulation 1995; 92:2245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/61\">",
"      Bitkover CY, G&aring;rdlund B. Mediastinitis after cardiovascular operations: a case-control study of risk factors. Ann Thorac Surg 1998; 65:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/62\">",
"      Trick WE, Scheckler WE, Tokars JI, et al. Modifiable risk factors associated with deep sternal site infection after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2000; 119:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/63\">",
"      Furnary AP, Zerr KJ, Grunkemeier GL, Starr A. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg 1999; 67:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/64\">",
"      Wouters R, Wellens F, Vanermen H, et al. Sternitis and mediastinitis after coronary artery bypass grafting. Analysis of risk factors. Tex Heart Inst J 1994; 21:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/65\">",
"      Blasco-Colmenares E, Perl TM, Guallar E, et al. Aspirin plus clopidogrel and risk of infection after coronary artery bypass surgery. Arch Intern Med 2009; 169:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/66\">",
"      L'Ecuyer PB, Murphy D, Little JR, Fraser VJ. The epidemiology of chest and leg wound infections following cardiothoracic surgery. Clin Infect Dis 1996; 22:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/67\">",
"      Slaughter MS, Olson MM, Lee JT Jr, Ward HB. A fifteen-year wound surveillance study after coronary artery bypass. Ann Thorac Surg 1993; 56:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/68\">",
"      Paletta CE, Huang DB, Fiore AC, et al. Major leg wound complications after saphenous vein harvest for coronary revascularization. Ann Thorac Surg 2000; 70:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/69\">",
"      Kiaii B, Moon BC, Massel D, et al. A prospective randomized trial of endoscopic versus conventional harvesting of the saphenous vein in coronary artery bypass surgery. J Thorac Cardiovasc Surg 2002; 123:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/70\">",
"      Schurr UP, Lachat ML, Reuthebuch O, et al. Endoscopic saphenous vein harvesting for CABG -- a randomized, prospective trial. Thorac Cardiovasc Surg 2002; 50:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/71\">",
"      Dacey LJ, Braxton JH Jr, Kramer RS, et al. Long-term outcomes of endoscopic vein harvesting after coronary artery bypass grafting. Circulation 2011; 123:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/72\">",
"      Swenne CL, Lindholm C, Borowiec J, Carlsson M. Surgical-site infections within 60 days of coronary artery by-pass graft surgery. J Hosp Infect 2004; 57:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/73\">",
"      Biancari F, Tiozzo V. Staples versus sutures for closing leg wounds after vein graft harvesting for coronary artery bypass surgery. Cochrane Database Syst Rev 2010; :CD008057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/74\">",
"      Williams JB, Peterson ED, Brennan JM, et al. Association between endoscopic vs open vein-graft harvesting and mortality, wound complications, and cardiovascular events in patients undergoing CABG surgery. JAMA 2012; 308:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/75\">",
"      Olsen MA, Krauss M, Agniel D, et al. Mortality associated with bloodstream infection after coronary artery bypass surgery. Clin Infect Dis 2008; 46:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/76\">",
"      Rosner MH, Okusa MD. Acute kidney injury associated with cardiac surgery. Clin J Am Soc Nephrol 2006; 1:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/77\">",
"      Vermeulen Windsant IC, Snoeijs MG, Hanssen SJ, et al. Hemolysis is associated with acute kidney injury during major aortic surgery. Kidney Int 2010; 77:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/78\">",
"      Palevsky PM. Epidemiology of acute renal failure: the tip of the iceberg. Clin J Am Soc Nephrol 2006; 1:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/79\">",
"      Loef BG, Epema AH, Smilde TD, et al. Immediate postoperative renal function deterioration in cardiac surgical patients predicts in-hospital mortality and long-term survival. J Am Soc Nephrol 2005; 16:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/80\">",
"      Del Duca D, Iqbal S, Rahme E, et al. Renal failure after cardiac surgery: timing of cardiac catheterization and other perioperative risk factors. Ann Thorac Surg 2007; 84:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/81\">",
"      Mack MJ, Brown PP, Kugelmass AD, et al. Current status and outcomes of coronary revascularization 1999 to 2002: 148,396 surgical and percutaneous procedures. Ann Thorac Surg 2004; 77:761.",
"     </a>",
"    </li>",
"    <li>",
"     2006 Data analysis report of the National Adult Cardiac Surgery Database of the Society of Thoracic Surgery.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/83\">",
"      Cooper WA, O'Brien SM, Thourani VH, et al. Impact of renal dysfunction on outcomes of coronary artery bypass surgery: results from the Society of Thoracic Surgeons National Adult Cardiac Database. Circulation 2006; 113:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/84\">",
"      Chertow GM, Lazarus JM, Christiansen CL, et al. Preoperative renal risk stratification. Circulation 1997; 95:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/85\">",
"      Thakar CV, Arrigain S, Worley S, et al. A clinical score to predict acute renal failure after cardiac surgery. J Am Soc Nephrol 2005; 16:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/86\">",
"      Mangano CM, Diamondstone LS, Ramsay JG, et al. Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization. The Multicenter Study of Perioperative Ischemia Research Group. Ann Intern Med 1998; 128:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/87\">",
"      Mehta RH, Honeycutt E, Patel UD, et al. Relationship of the time interval between cardiac catheterization and elective coronary artery bypass surgery with postprocedural acute kidney injury. Circulation 2011; 124:S149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/88\">",
"      Karkouti K, Wijeysundera DN, Yau TM, et al. Acute kidney injury after cardiac surgery: focus on modifiable risk factors. Circulation 2009; 119:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/89\">",
"      Billings FT 4th, Pretorius M, Schildcrout JS, et al. Obesity and oxidative stress predict AKI after cardiac surgery. J Am Soc Nephrol 2012; 23:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/90\">",
"      Haase M, Bellomo R, Matalanis G, et al. A comparison of the RIFLE and Acute Kidney Injury Network classifications for cardiac surgery-associated acute kidney injury: a prospective cohort study. J Thorac Cardiovasc Surg 2009; 138:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/91\">",
"      Demirjian S, Schold JD, Navia J, et al. Predictive models for acute kidney injury following cardiac surgery. Am J Kidney Dis 2012; 59:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/92\">",
"      Goldhaber SZ, Schoepf UJ. Pulmonary embolism after coronary artery bypass grafting. Circulation 2004; 109:2712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/93\">",
"      Goldhaber SZ, Hirsch DR, MacDougall RC, et al. Prevention of venous thrombosis after coronary artery bypass surgery (a randomized trial comparing two mechanical prophylaxis strategies). Am J Cardiol 1995; 76:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/94\">",
"      White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost 2003; 90:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/95\">",
"      Sadikot RT, Rogers JT, Cheng DS, et al. Pleural fluid characteristics of patients with symptomatic pleural effusion after coronary artery bypass graft surgery. Arch Intern Med 2000; 160:2665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/96\">",
"      Nicholson WJ, Crawley IS, Logue RB, et al. Aortic root dissection complicating coronary bypass surgery. Am J Cardiol 1978; 41:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/97\">",
"      Hagl C, Ergin MA, Galla JD, et al. Delayed chronic type A dissection following CABG: implications for evolving techniques of revascularization. J Card Surg 2000; 15:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/98\">",
"      Chavanon O, Carrier M, Cartier R, et al. Increased incidence of acute ascending aortic dissection with off-pump aortocoronary bypass surgery? Ann Thorac Surg 2001; 71:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/99\">",
"      De Smet JM, Stefanidis C. Acute aortic dissection after off-pump coronary artery surgery. Eur J Cardiothorac Surg 2003; 24:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/100\">",
"      Kimmel SE, Sekeres MA, Berlin JA, et al. Risk factors for clinically important adverse events after protamine administration following cardiopulmonary bypass. J Am Coll Cardiol 1998; 32:1916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/101\">",
"      Bauer TL, Arepally G, Konkle BA, et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 1997; 95:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/102\">",
"      Warkentin TE. Heparin-induced thrombocytopenia: a clinicopathologic syndrome. Thromb Haemost 1999; 82:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/103\">",
"      P&ouml;tzsch B, Kl&ouml;vekorn WP, Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J Med 2000; 343:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/104\">",
"      Liu JC, Lewis BE, Steen LH, et al. Patency of coronary artery bypass grafts in patients with heparin-induced thrombocytopenia. Am J Cardiol 2002; 89:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/105\">",
"      Mangi AA, Christison-Lagay ER, Torchiana DF, et al. Gastrointestinal complications in patients undergoing heart operation: an analysis of 8709 consecutive cardiac surgical patients. Ann Surg 2005; 241:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/106\">",
"      Filsoufi F, Rahmanian PB, Castillo JG, et al. Predictors and outcome of gastrointestinal complications in patients undergoing cardiac surgery. Ann Surg 2007; 246:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/107\">",
"      Rodriguez F, Nguyen TC, Galanko JA, Morton J. Gastrointestinal complications after coronary artery bypass grafting: a national study of morbidity and mortality predictors. J Am Coll Surg 2007; 205:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/108\">",
"      Hannan EL, Zhong Y, Lahey SJ, et al. 30-day readmissions after coronary artery bypass graft surgery in New York State. JACC Cardiovasc Interv 2011; 4:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/109\">",
"      D'Agostino RS, Jacobson J, Clarkson M, et al. Readmission after cardiac operations: prevalence, patterns, and predisposing factors. J Thorac Cardiovasc Surg 1999; 118:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/110\">",
"      Stewart RD, Campos CT, Jennings B, et al. Predictors of 30-day hospital readmission after coronary artery bypass. Ann Thorac Surg 2000; 70:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/111\">",
"      Vaccarino V, Lin ZQ, Kasl SV, et al. Gender differences in recovery after coronary artery bypass surgery. J Am Coll Cardiol 2003; 41:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/25/35226/abstract/112\">",
"      Hannan EL, Racz MJ, Walford G, et al. Predictors of readmission for complications of coronary artery bypass graft surgery. JAMA 2003; 290:773.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1585 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-8189A37D88-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_25_35226=[""].join("\n");
var outline_f34_25_35226=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H99231126\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVENTION OF COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Minimal extracorporeal CPB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Improvements in surgical technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Medical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Minimally invasive CABG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Antiplatelet agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H534837610\">",
"      Stopping and restarting P2Y12 receptor blocker",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Antifibrinolytic agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1916969895\">",
"      - Leukoreduced blood",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Duration of red cell storage and outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      NEUROLOGIC COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Sternal wound infection and mediastinitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Leg wound complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Recurrent cellulitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Bloodstream infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      ACUTE KIDNEY INJURY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      OTHER COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Venous thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Pulmonary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Protamine reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Gastrointestinal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      EARLY READMISSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H99231126\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1585\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1585|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/21/14685\" title=\"figure 1\">",
"      Impact of age on adverse cerebral outcomes after CABG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1585|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=related_link\">",
"      Antiplatelet agents in acute non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10634?source=related_link\">",
"      Antiplatelet therapy after coronary artery stenting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35305?source=related_link\">",
"      Approach to the diagnosis and therapy of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28602?source=related_link\">",
"      Atrial fibrillation and flutter after cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/19/25914?source=related_link\">",
"      Clinical manifestations and diagnosis of aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/29/6617?source=related_link\">",
"      Coronary artery bypass grafting in patients with cerebrovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/15/30970?source=related_link\">",
"      Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/28/39368?source=related_link\">",
"      Early cardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10809?source=related_link\">",
"      Embolism from aortic plaque: Thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40890?source=related_link\">",
"      Heparin-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11769?source=related_link\">",
"      Immunologic blood transfusion reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/52/5961?source=related_link\">",
"      Indications for red cell transfusion in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/5/24665?source=related_link\">",
"      Leukoreduction to prevent complications of blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/2/37930?source=related_link\">",
"      Long-term outcome after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/26/40360?source=related_link\">",
"      Medical therapy to prevent complications after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/51/9018?source=related_link\">",
"      Medical therapy versus revascularization in the management of stable angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/16/44296?source=related_link\">",
"      Minimally invasive coronary artery bypass graft surgery: Definitions and technical issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/47/3834?source=related_link\">",
"      Neurologic complications of cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37031?source=related_link\">",
"      Off-pump and minimally invasive direct coronary artery bypass graft surgery: Outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/38/22120?source=related_link\">",
"      Operative mortality after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4170?source=related_link\">",
"      Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10457?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/62/31717?source=related_link\">",
"      Patient information: Coronary artery bypass graft surgery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/16/23813?source=related_link\">",
"      Patient information: Recovery after coronary artery bypass graft surgery (CABG) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/45/40666?source=related_link\">",
"      Perioperative medication management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/59/23482?source=related_link\">",
"      Platelet function testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/21/16728?source=related_link\">",
"      Pleural effusions following cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/10/42154?source=related_link\">",
"      Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/40/38537?source=related_link\">",
"      Postoperative complications among patients undergoing cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/48/1800?source=related_link\">",
"      Postoperative mediastinitis after cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/7/2168?source=related_link\">",
"      Prevention of neurologic complications of cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/44/24262?source=related_link\">",
"      Recurrent cellulitis after saphenous venectomy for coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/38/10854?source=related_link\">",
"      Regulators and receptors of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/51/13113?source=related_link\">",
"      Strategies to reduce postoperative pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14858?source=related_link\">",
"      Surgical management of sternal wound complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/46/10986?source=related_link\">",
"      The approach to the patient who refuses blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/28/31175?source=related_link\">",
"      Transfusion transmitted HIV infection and AIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/14/10471?source=related_link\">",
"      Transfusion transmitted bacterial infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/56/37766?source=related_link\">",
"      Transfusion-associated immune and non immune-mediated hemolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/39/28282?source=related_link\">",
"      Transfusion-related acute lung injury (TRALI)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/37/21081?source=related_link\">",
"      Use of red blood cells for transfusion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_25_35227="ESC recommendations carotid sinus massage";
var content_f34_25_35227=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69426&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69426&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    European Society of Cardiology recommendations for carotid sinus massage",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Recommendations",
"       </td>",
"       <td class=\"subtitle1\">",
"        Class*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Level",
"        <span class=\"small\">",
"         &bull;",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Indications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CSM is indicated in patients &gt;40 years with syncope of unknown aetiology after initial evaluation",
"       </td>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CSM should be avoided in patients with previous TIA or stroke within the past&nbsp;three months and in patients with carotid bruits (except if carotid Doppler studies excluded significant stenosis)",
"       </td>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Diagnostic criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CSM is diagnostic if syncope is reproduced in the presence of asystole longer than 3 s and/or a fall in systolic BP &gt;50 mmHg",
"       </td>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        B",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BP: blood pressure; CSM: carotid sinus massage; TIA: transient ischaemic attack.",
"     <br>",
"      * Class of recommendation.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Level of evidence.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: European Heart Rhythm Association (EHRA), Heart Failure Association (HFA), Heart Rhythm Society (HRS), et al. Guidelines for the diagnosis and management of syncope (version 2009): the Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC). Eur Heart J 2009; 30:2631. Copyright &copy; 2009 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_25_35227=[""].join("\n");
var outline_f34_25_35227=null;
var title_f34_25_35228="ACLS AF rate rhythm control II";
var content_f34_25_35228=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F80760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F80760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for the control of rate and rhythm in atrial fibrillation/flutter-II",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Control rate",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Convert rhythm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Cardiac function preservation",
"       </td>",
"       <td class=\"subtitle2\">",
"        Impaired cardiac function EF &lt;40 percent of HF",
"       </td>",
"       <td class=\"subtitle2\">",
"        Duration &lt;48 hours",
"       </td>",
"       <td class=\"subtitle2\">",
"        Duration &gt;48 hours or unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        WPW",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Note: IF AF &gt;48 hours duration, use agents to convert rhythm with extreme caution in patients not receiving adequate anticoagulation because of possible embolic complications.",
"        </p>",
"        <p>",
"         DC cardioversion",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Primary anti- arrhythmic agents-",
"        </p>",
"        <p>",
"         Use only 1 of the following agents:",
"        </p>",
"        <p>",
"         Amiodarone",
"        </p>",
"        <p>",
"         Flecainide (Class IIb)",
"        </p>",
"        <p>",
"         Procainamide (Class IIb)",
"        </p>",
"        <p>",
"         Propafenone (Class IIb)",
"        </p>",
"        <p>",
"         Sotalol (Class IIb)",
"        </p>",
"        <p>",
"         <strong>",
"          Class III (can be harmful)",
"         </strong>",
"        </p>",
"        <p>",
"         Adenosine",
"        </p>",
"        <p>",
"         Beta-blockers",
"        </p>",
"        <p>",
"         Calcium blockers",
"        </p>",
"        <p>",
"         Digoxin",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Note: If AF &gt;48 hours duration, use agents to convert rhythm with extreme caution in patients not receiving adequate anticoagulation because of possible embolic complications.",
"        </p>",
"        <p>",
"         DC cardioversion",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Amiodarone (Class IIb)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         DC cardioversion",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Primary anti-arrhythmic agents",
"        </p>",
"        <p>",
"         Use only 1 of the following agents:",
"        </p>",
"        <p>",
"         Amiodarone (Class IIb)",
"        </p>",
"        <p>",
"         Flecainide (Class llb)",
"        </p>",
"        <p>",
"         Procainamide (Class Ilb)",
"        </p>",
"        <p>",
"         Propafenone (Class lIb)",
"        </p>",
"        <p>",
"         Sotalol",
"        </p>",
"        <p>",
"         <strong>",
"          Class III (can be harmful)",
"         </strong>",
"        </p>",
"        <p>",
"         Adenosine",
"        </p>",
"        <p>",
"         Beta-blockers",
"        </p>",
"        <p>",
"         Calcium blockers",
"        </p>",
"        <p>",
"         Digoxin",
"        </p>",
"       </td>",
"       <td>",
"        Anticoagulation followed by DC cardioversion",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: Occasionally 2 of the named antiarrhythmic agents may be used, but use of these agents in combination may have proarrhythmic potential. The classes listed represent the AHA Class of Recommendation and not the Vaughn-Williams classification of antiarrhythmics.",
"    <div class=\"footnotes\">",
"     WPW: Wolff-Parkinson-White syndrome; AF: atrial fibrillation; NSR: normal sinus rhythm; EF: ejection fraction; HF: heart failure.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 6: Circulation 2000 I-158.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_25_35228=[""].join("\n");
var outline_f34_25_35228=null;
var title_f34_25_35229="Dietary sources of absorbable calcium";
var content_f34_25_35229=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52445&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52445&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dietary sources of absorbable calcium, in comparison to milk",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Food",
"       </td>",
"       <td class=\"subtitle1\">",
"        Serving size* (g)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Calcium content&bull; (mg)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Fractional absorption&Delta;, (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Estimated absorbable calcium&loz; (mg)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of servings needed to equal 240 mL milk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Milk",
"       </td>",
"       <td>",
"        240",
"       </td>",
"       <td>",
"        300",
"       </td>",
"       <td>",
"        32.1",
"       </td>",
"       <td>",
"        96.3",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"6\">",
"        Beans",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1 sublist1\">",
"        Pinto",
"       </td>",
"       <td class=\"sublist_other\">",
"        86",
"       </td>",
"       <td class=\"sublist_other\">",
"        44.7",
"       </td>",
"       <td class=\"sublist_other\">",
"        26.7",
"       </td>",
"       <td class=\"sublist_other\">",
"        11.9",
"       </td>",
"       <td class=\"sublist_other\">",
"        8.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1 sublist1\">",
"        Red",
"       </td>",
"       <td class=\"sublist_other\">",
"        172",
"       </td>",
"       <td class=\"sublist_other\">",
"        40.5",
"       </td>",
"       <td class=\"sublist_other\">",
"        24.4",
"       </td>",
"       <td class=\"sublist_other\">",
"        9.9",
"       </td>",
"       <td class=\"sublist_other\">",
"        9.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1 sublist1\">",
"        White",
"       </td>",
"       <td class=\"sublist_other\">",
"        110",
"       </td>",
"       <td class=\"sublist_other\">",
"        113",
"       </td>",
"       <td class=\"sublist_other\">",
"        21.8",
"       </td>",
"       <td class=\"sublist_other\">",
"        24.7",
"       </td>",
"       <td class=\"sublist_other\">",
"        3.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bok choy",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        53.8",
"       </td>",
"       <td>",
"        42.5",
"       </td>",
"       <td>",
"        2.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Broccoli",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        61.3",
"       </td>",
"       <td>",
"        21.5",
"       </td>",
"       <td>",
"        4.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cheddar cheese",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        303",
"       </td>",
"       <td>",
"        32.1",
"       </td>",
"       <td>",
"        97.2",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cheese food",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        241",
"       </td>",
"       <td>",
"        32.1",
"       </td>",
"       <td>",
"        77.4",
"       </td>",
"       <td>",
"        1.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chinese cabbage flower leaves",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        239",
"       </td>",
"       <td>",
"        39.6",
"       </td>",
"       <td>",
"        94.7",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chinese mustard greens",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        212",
"       </td>",
"       <td>",
"        40.2",
"       </td>",
"       <td>",
"        85.3",
"       </td>",
"       <td>",
"        1.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fruit punch with calcium citrate malate",
"       </td>",
"       <td>",
"        240",
"       </td>",
"       <td>",
"        300",
"       </td>",
"       <td>",
"        52.0",
"       </td>",
"       <td>",
"        156",
"       </td>",
"       <td>",
"        0.62",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kale",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        49.3",
"       </td>",
"       <td>",
"        30.1",
"       </td>",
"       <td>",
"        3.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spinach",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        115",
"       </td>",
"       <td>",
"        5.1",
"       </td>",
"       <td>",
"        5.9",
"       </td>",
"       <td>",
"        16.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sweet potatoes",
"       </td>",
"       <td>",
"        164",
"       </td>",
"       <td>",
"        44",
"       </td>",
"       <td>",
"        22.2",
"       </td>",
"       <td>",
"        9.8",
"       </td>",
"       <td>",
"        9.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rhubarb",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        174",
"       </td>",
"       <td>",
"        8.54",
"       </td>",
"       <td>",
"        10.1",
"       </td>",
"       <td>",
"        9.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tofu with calcium",
"       </td>",
"       <td>",
"        126",
"       </td>",
"       <td>",
"        258",
"       </td>",
"       <td>",
"        31.0",
"       </td>",
"       <td>",
"        80.0",
"       </td>",
"       <td>",
"        1.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yogurt",
"       </td>",
"       <td>",
"        240",
"       </td>",
"       <td>",
"        300",
"       </td>",
"       <td>",
"        32.1",
"       </td>",
"       <td>",
"        96.3",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Based on half-cup serving size (~85 g for green leafy vegetables) except for milk and fruit punch (1 cup or 240 mL) and cheese (1.5 ounces).",
"     <br>",
"      &bull; From references 4 and 5 (averaged for beans and broccoli processed in different ways) except for the Chinese vegetables, which were analyzed in our laboratory.",
"      <br>",
"       &Delta; Adjusted for load by using the equation for milk (fractional absorption = 0.889-0.0964 in load (6)) then adjusted for the ratio of calcium absorption of the test food relative to milk tested at the same load, the absorptive index. The absorptive index was taken from the literature for beans (7), bok choy (8), broccoli (8), Chinese vegetables (9), fruit punch with calcium citrate mulate (10), kale (8), sweet potatoes (9), rhubarb (9), tofu (11), and dairy products (12).",
"       <br>",
"        &loz; Calculated as calcium content x fractional absorption.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Weaver CM, Proulx WR, Heaney R. Choices for achieving adequate dietary calcium with a vegetarian diet. Am J Clin Nutr 1999; 70 (suppl):543S. Copyright &copy;1999, American Society for Clinical Nutrition.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_25_35229=[""].join("\n");
var outline_f34_25_35229=null;
var title_f34_25_35230="CNS lymphoma PCR study";
var content_f34_25_35230=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F81109&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F81109&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 491px\">",
"   <div class=\"ttl\">",
"    Polymerase chain reaction of cells from the cerebrospinal fluid demonstrate lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 471px; height: 219px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This gel shows PCR results for three CSF samples (marked 1,2,3) from the same patient with lymphomatous meningitis. Also shown is a negative control (N), a sample from a patient with infection (polyclonal, P), and a positive control (C). The narrow bands seen for the patient's samples (arrows) and the positive control indicate a uniform population of cells with the same immunoglobulin heavy chain (IgH) rearrangement.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_25_35230=[""].join("\n");
var outline_f34_25_35230=null;
var title_f34_25_35231="BRAO cholesterol plaque";
var content_f34_25_35231=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F76602&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F76602&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    BRAO cholesterol plaque",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 169px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Cholesterol plaque in a branch retinal artery. B) The cholesterol plaque has moved through the retinal circulation and is no longer visible.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_25_35231=[""].join("\n");
var outline_f34_25_35231=null;
